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Part I. Peptides: properties, activity, and applications 
1.1 Peptides - General aspects 
Peptides and proteins form a highly diverse group of macromolecular compounds 
consisting of chains of α-amino acids linked by amide bonds between the carboxylate 
groups and amino groups. Proteins and peptides have the same general chemical 
structure, but the name ‘peptides’ is often restricted to chains with an upper size limit of 
about 50 amino acids, or a molecular mass of about 6,000 Da 1. While large proteins 
often act as catalysts (enzymes) or structural proteins (keratin, collagen), smaller 
naturally occurring peptides are more usually involved in regulatory processes in 
organisms. The diversity of such peptides is enormous, their occurrence is widespread, 
and they play essential roles in processes such as regulation of metabolic activity, 
immune response, hormone secretion and cellular defense. Probably the most known 
example is the hormone insulin, which is composed of 2 cross-linked chains of 21 and 30 
amino acids with a total mass of 5773 Da, and controls serum glucose levels. Other 
peptide-mediated activities include cell to cell communication, control of neurological 
processes (neurotransmitters, neuromodulators, e.g. influencing pain sensation), and 
regulation of fertility 2,3. 
The multitude of activities attributed to peptides has sparked widespread interest 
in developing and using peptides in different industries and biomedical applications. 
This varies from a simple dipeptide aspartame (Asp-Phe-OCH3) which is used as an 
artificial sweetener in foods and drinks, to numerous large peptides that influence 
metabolism, cell proliferation, or other processes. The use of peptides as therapeutic 
drugs is attractive because of their high activity and specificity, as well as low toxicity 
(with exceptions) and low tendency to accumulate in tissues. Synthetic peptides can also 
be used as antigens, enzyme substrates, and inhibitors that influence signaling pathways 
in biomedical research. They may be used as probes for in vivo diagnostic purposes. 
Peptides or peptide tags can facilitate protein purification when used as immobilized 
affinity ligands and can interfere with protein-protein interactions. Peptides are also 
developed for use in molecular electronic devices 1,2. 
The importance of peptides in healthcare, nutrition, and cosmetics triggered 
widespread interest in methodologies for peptide synthesis and characterization. 
However, production of peptides at large scale is challenging at this moment, and 
efficient platforms for cost-efficient and environment-friendly production of peptides are 
still in high demand 4,5. The use of enzymes for peptide synthesis is of special interest 
since it avoids harsh reaction conditions that may lead to the formation of unwanted side 
products. Furthermore, peptides often need to be modified to improve their application 
potential 6. This is especially true for pharmaceutical peptides where modification 
influences pharmacokinetics and interaction with target molecules. The use of enzymes 
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for peptide synthesis and especially modification is the topic of this thesis and is further 
examined in this introductory chapter, after discussing the use of peptides in various 
applications in more detail. 
1.2 Therapeutic peptides 
In the pharmaceutical industry, peptide-based therapeutic agents comprise the 
fastest growing market segment. Currently, 68 approved peptide-based drugs are 
commercialized, several of which generate multibillion-dollar sales annually 7. The 
majority of these peptides consist of about 8-10 amino acids. The market for therapeutic 
peptides is projected to surpass US$ 70 billion in 2018-2019, corresponding to an annual 
growth rate of 9 to 10%, which is faster than that of other pharmaceuticals8. Furthermore, 
peptide-based drugs currently represent over 15% of the total number of new entities 
registered by the U.S. Food & Drug Administration (FDA) 9,10. Over 300 companies are 
involved in developing 292 peptide-based drugs in 780 oncology projects, according to a 
survey of ClinicalTrials.gov 11,12. In 2018, around 500 to 600 peptides are in preclinical 
development, while 155 peptides are examined in clinical trials and 97% of them are 
expected to pass the regulatory phase 7,13. Most of these trials are targeting cancer, 
metabolic diseases, and cardiovascular problems 7,8. The success rate is nearly twice as 
that of the small molecule drugs 13,14. 
Most peptide therapeutics target metabolic disorders, fertility problems, cancer, 
and problems associated with the central nervous system. Examples of peptide 
therapeutics that have entered the market include glatiramer acetate (Copaxone, 10 
amino acids) used for treatment of multiple sclerosis, the gonadotropin antagonist 
leuprorelin (Lupron, 9 amino acids), exenatide (Byetta, 39 amino acids) for type II 
diabetes, and enfuvirtide (T-20/Fuzeon, 36 amino acids), which inhibits HIV-1 
membrane fusion 8. More examples of recently introduced pharmaceutical peptides are 
listed in Table 1. Peptide therapeutics are also being developed for cardiovascular 
disorders, infection management (see next section), hematological disorders, 
gastrointestinal disorders, dermatological problems, respiratory disorders, and hormone 
metabolism.12 Following the sequencing of the human genome, peptides have become 
an important focus of biotechnological research due to the increasing awareness of their 
key role in regulation and immunity. The discovery of new targets with which peptides 


















Plasma membrane synthesis 
inhibition 
2003 









Ziconotide 25 Chronic pain N-type Ca Channel blocker 2004 
Pramlintide 37 
Types 1 and 2 
diabetes 
Calcitonin agonist 2005 
Exenatide 39 Type 2 diabetes GLP-1b receptor agonist 2005 




Bradykinin B2 receptor 
antagonist 
2008 
Degarelix 10 Prostate cancer GnRHc antagonist 2008 




Plasma kallikrein inhibitor 2009 
Liraglutide 30 Type 2 diabetes GLP-1 receptor agonist 2010 





Peginesatide 40 Anemia Erythropoietin analog 2012 




Guanidyl cyclase 2C agonist 2012 




GLP-2 analog 2012 
Lixisenatidee 44 Type 2 diabetes GLP-1 receptor agonist 2013 
Albiglutide 60 Type 2 diabetes GLP-1 receptor agonist 2014 








Guanylate cyclase C agonist 2017 
Abaloparatide 34 Osteoporosis 
Parathyroid hormone 
related peptide (PTHrP) 
analog 
2017 
a Luteinizing hormone-releasing hormone 
b Glucagon-like peptide-1 
c Gonadotropin-releasing hormone 
d Growth hormone-releasing hormone 
e Lixisenatide was approved in the US in 2016 and in Europe in 2013 
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1.2.1 Anti-infective peptides 
Over the past seven decades, antibiotics have saved numerous lives and 
contributed to the growing life expectancy of humans. Nevertheless, due to emerging 
antibiotic resistance and increased regulations concerning side effects, new anti-infective 
therapies have to be developed. The problem is serious; it has been predicted that more 
deaths will be caused by drug-resistant bacterial infections than by cancer in 2050 21. 
Widespread resistance could result in bringing humans back to the pre-antibiotic world 
22. Consequently, there is a growing demand for non-conventional approaches to treating 
infections caused by pathogenic bacteria. Peptide-based antibiotics are deemed to fill 
the void created by growing antibiotic resistance. Therefore, studies towards 
pharmacological development of peptides are on the rise 23. The use of antimicrobial 
peptides (AMPs), either synthetic or of natural origin, offers several clinical advantages 
over other chemotherapies, i.e. broad-spectrum activity, rapid action, low target-based 
resistance and low immunogenicity 24. 
Also known as host defense peptides (HDPs), natural AMPs were first discovered 
on the external surfaces of amphibians three decades ago 25. Since then, they have been 
found from a variety of organisms belonging to all kingdoms of life. Apart from 
antimicrobial activity, they also may exhibit anticancer, anti-biofilm, spermicidal, or 
mitogenic activities. By their mode of action, AMPs can be broadly classified into two 
groups. While one group of HDPs exhibits direct and broad-spectrum antimicrobial 
activity, the other group modulates the innate immune response of the host 26. Being very 
diverse in nature, AMPs have different chemical structures and conformations but with 
certain common properties, for example, small size (12-50 amino acids long), and either 
linear or cyclic structures with cationic and hydrophobic sequences 27. This amphipathic 
structure enables AMPs to bind to membranes and they have a general mode of action 
28,29. 
AMPs have been found to act on a variety of pathogens including bacteria, fungi, 
parasites, and viruses. The majority of AMPs exert their biological activity via: a) 
membrane disruption or membrane pore formation – such as melittin, LL-37 MSI-78; b) 
inhibition of cell wall synthesis – such as Class I bacteriocins, nisin, Pep5 etc.; c) 
inhibition of protein, RNA and DNA synthesis – such as buforin II and pleurocidin 30–35. 
Synthetic AMPs (e.g. brilacidin - a mimetic of magainin, currently in phase II) have been 
developed that selectively damage the microbial membrane 36,37. Amongst innate 
immunity modulators, defensins can induce several cytokines such as TNF and IL-1 in 
monocytes, and IL-8 in lung epithelial cells. Defensins are also potent chemo-attractants 
for monocytes and neutrophils. For example, LL-37, CRAMP, α-defensins, and β-
defensins are known chemo-attractants for monocytes, macrophages, T cells, 
neutrophils, immature dendritic cells, and mast cells 31,38,39. AMPs are also known to 




monocytes or other antigen-presenting cells. For example, melittin from bees enhances 
a mixed Th1/Th2 response to tetanus toxoid in mice by promoting IgG and IgG2a 
antibody production. They can modulate chemokine and cytokine responses depending 
on their concentration and the order of exposure to cells. They can also facilitate wound 
healing and angiogenesis. For example, histatin and LL-37 induce fibroblast migration 
and proliferation 40,41. 
There are various databases from which information on naturally occurring 
peptides can be retrieved online. To date, 17,353 antimicrobial peptide sequences can be 
retrieved, of which 12,704 are patented peptide sequences 42–51. The number of such 
peptides is expected to increase in the future owing to the technological advances in 
peptide discovery and synthesis, hopefully leading to new antimicrobial drugs with high 
target affinity and fewer side effects 15.  
AMPs are attractive targets regarding human health due to their selective toxicity 
against bacteria. Some AMPs are extremely target-selective so that very narrow spectrum 
drugs can be developed, a property that is highly desired since it lowers the chances of 
emerging and spread of resistances 52. Currently, AMPs are mainly being studied as single 
anti-infective agents, but they also are examined in combination with conventional 
antibiotics or antivirals to promote additive or synergistic effects. A combination could 
be an immune-stimulatory agent to enhance innate immunity, and an endotoxin-
neutralizing agent to prevent septic shock caused by fatal complications of bacterial 
virulence factors 53. Table 2 lists some of the AMPs in clinical development. 
1.2.2 Anti-cancer peptides 
Peptides may exhibit anti-cancer activity through different mechanisms. Earlier 
peptides for cancer treatment were found by searching for regulatory peptides that target 
overexpressed G-protein coupled receptors on cancer cells. One of these peptides, 
somatostatin (a 14-residue cyclic neuropeptide, SST) was found to target five G-protein 
coupled receptors, one or a few of which are overexpressed in tumor tissues 54. This led 
to the development of an SST analog, the disulfide-cross linked octapeptide octreotide, 
which is being used for the treatment of growth hormone-secreting pituitary adenomas 
55. Later on, multi-receptor binding analogs with higher biostability and affinity were 
developed, such as pasireotide and somatoprim, which are in clinical trials for octreotide-
resistant tumors 56. 
Host defense peptides can also have antitumor activity and may specifically target 
cancer cell membranes 26,59. Magainin 2 and its derivatives are the very first HDPs 
investigated for anticancer activity. In animal models, these peptides destroy cancer cells 
via cell membrane lysis and apoptosis, which is very similar to their antimicrobial action. 
However, multiple modes of action have been proposed for a single HDP 26,60. Peptides 
that target the vasculature supplying nutrients and oxygen to tumor tissue are also being 
developed. These vessels overexpress a number of receptor targets including adhesion 
General introduction: enzymatic synthesis of bioactive peptides 
 
 
molecules – αv integrins. The best examples of such tumor-targeting peptides are the 
RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) peptides that are currently in clinical trials 
61. The RGD motif is found in many extracellular matrix proteins and targets αvβ3 integrin 
receptors that are expressed on tumor cells. Consequently, the RGD motif serves as a 
template for designing peptides that target not only αvβ3 integrins but also other integrins 
expressed during angiogenesis 62. The NGR peptide, on the other hand, targets 
aminopeptidase N (CD13), an embedded metalloprotease that is overexpressed in tumor 
vasculature. The NGR peptide has a high affinity for the active site of the enzyme but is 
resistant to degradation. Various peptides are under studies that utilize the NGR motif 
as a selective tool for drug delivery and tumor imaging 63. A modern approach to delivery 
is conjugating cancer-targeting peptides with nanoparticles. Such conjugates exhibit 
highly tunable properties for imaging or killing cancer cells. A recent example is the use 
of iRGD (CRGDKGPDC) conjugated to carbon nanodots to enhance fluorescence signals 
Table 2. Examples of anti-infective peptides in clinical development 35,57,58 







Prevention of intravascular 
local catheter infection 
Phase III 
Pexiganan (MSI-78) Magainin analog 
Topical agent for mild 
diabetic foot infection 
Phase III 
Iseganan (IB-367) 
















S. aureus and Ps. aeruginosa Preclinical 
Antifungal peptides 
Novexatin (NP213) Cyclic cationic peptide Onychomycosis Phase II 
CZEN-002  
  
Synthetic octapeptide Vulvovaginal candidiasis Phase II 
PAC-113 (P-113) 
12 amino acid histatin 
derivative 




Systemic candidiasis Preclinical 
Antiviral peptides    
Fuzeon (enfuvirtide) Synthetic peptide HIV-infection Marketed 
Tat protein HIV-1 TAT protein HIV-1 Preclinical 
RhoA (peptide 77-98) 
Fragment of RhoA 
GTPase 
Human respiratory syncytial 
parainfluenza virus-3, HIV-1 
Preclinical 








in tumor imaging 64. Peptides are being engineered with improved immunogenicity, 
higher specificity in cancer and better mimicking of tumor-associated antigens 65. 
Peptides are being investigated as anti-cancer vaccines as well. For example, 
human papillomavirus (HPV) vaccine for cervical cancers (Gardasil, Gardasil9, and 
Cervarix) and hepatitis B vaccines for liver cancers have been approved by the FDA 66. 
Most of the peptide vaccines focus on the T-cell epitopes, which are able to recognize 
small peptides, causing a stimulation of the immune system. Several peptide-based 
cancer vaccines have entered clinical trials, including a vaccine that targets human 
epidermal growth factor receptor 2 (HER-2) in breast, lung and ovarian cancer 67. 
Recently, B-cell epitopes of proto-oncogene proteins were used to develop vaccines, such 
as the HER-2 vaccine that prevents mammary tumors in transgenic and transplantable 
mouse models of breast cancer 68. These vaccines induce immunological memory against 
cancer-inducing agents and specific cancer cell antigens. Peptide vaccines provide a 
highly modifiable system but a perfect vaccine that preempts the development of cancer 
has to be established 69. 
The anti-cancer applications hold the largest share in peptide therapeutics and 
the field is still expanding. With the development of new screening and delivery 
techniques, the scope for anti-cancer therapeutic peptides will continue to expand 8,69. 
Table 3 provides some examples of peptides in clinical trials related to oncology studies. 
1.2.3 Peptides for treatment of metabolic and CNS disorders 
Most metabolic disorders are related to hormonal malfunction, including growth 
hormone deficiency, osteoporosis, diabetes, and obesity. Diabetes is the more prevalent 
disorder and it often brings other associated disorders as well. As peptide and protein 
hormones play a major role in balancing metabolic processes, the use of peptides and 
peptide analogs is a very successful therapeutic strategy. For example, insulin is essential 
for the control of glucose homeostasis, and a deficiency leads to diabetes mellitus. 
Commercial production of insulin started in 1922 from animal sources. In 1978, insulin 
was prepared by recombinant technology and approved by the FDA. The first human 
insulin analog was approved in 1996 as Lispro. In 2006, Exubera, an inhalable insulin, 
was approved. At this moment, more than 300 human insulin analogs have been 
identified consisting of 70 animal, 80 chemically modified, and 150 biosynthetic 
insulins. Modern insulin analogs mostly fall into two categories, viz., fast and short-
acting insulins that mimic the action of endogenous insulin (bolus insulin, e.g. lispro, 
glulisine and aspart), and the basal (background) insulin analogs with long-acting 
profiles (e.g. Glargine) 70. 
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Recently, glucagon-like peptide-1 (GLP-1) receptor agonists have been developed 
for Type 2 diabetes (T2DM). These compounds help in diabetes control by the incretin 
effect of glucose-dependent insulin release, which is mediated by GLP-1. Exenatide, a 
synthetic version of exendin-4 from the Gila monster lizard, was the first GLP-1 receptor 
agonist to enter the market. Another GLP-1 agonist, Lixisenatide, was later introduced 
with prolonged action. Liraglutide and Semaglutide are based on endogenous GLP-1 with 
subtle modifications in the original peptide chain 72,73. Recently, glucagon/GLP-1 dual 
acting (GGDA) hybrid peptides and GLP-1/gastrin dual acting fusion peptides were 
developed. Peptides such as the GGDA peptide ZP2929 and the GLP-1/gastrin fusion 
peptide ZP3022 are now in early phase clinical trials 70,74. 
Table 3. Examples of anti-cancer peptides in clinical development 65,69,71 
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Phase II Breast cancer 
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Many neuropeptides play a central role in regulating cellular and intercellular 
physiological responses in the central nervous system (CNS). This suggests they could 
lead to interesting therapeutic targets for the treatment of CNS disorders. Accordingly, 
peptides indeed are the forefront leads for the treatment of CNS diseases such as 
schizophrenia, anxiety, ischemia, degenerative diseases and pain syndromes. Agonists 
acting in the central nervous system on the neurotensin, cholecystokinin, neuropeptide 
Y and oxytocin receptors are the major targets for peptide drug development 75–77. For 
example, an (AuNP)-LPFFD conjugate radiolabeled with 18F was studied for the diagnosis 
and treatment of Alzheimer’s disease (AD) 78. Polymer-coupled neuropeptides are also 
investigated for inhibition of amyloid-β peptides occurring in brain lesions of AD 
patients 79,80. Furthermore, the vasoactive intestinal peptide of the glucagon/secretin 
superfamily and its receptors are interesting leads for treatment of Parkinson’s disease 81. 
Opioid neuropeptides (e.g. enkephalins, dynorphins, endorphins, nociceptin) acting on 
G-protein-coupled receptors are considered as potential therapeutics for AD as well. 
These peptides are involved in the neuroinflammatory components of AD 82–84. Peptide 
hormones such as vasopressin and oxytocin are also found to elicit secondary effects that 
are of interest in the treatment of memory loss and anxiolytic activity 85,86. Recently, GLP-
1 receptor agonists (e.g. exenatide) were shown to improve motor and cognitive function 
in persons with Parkinson’s disease. It is predicted that many of the peptides that are 
used for the treatment of metabolic disorders could also be used to treat CNS disorders 
due to the common pathophysiology 87. 
Most of the peptide leads for therapy of CNS disorders are in the initial stages of 
development. Although they show a huge potential for diagnosis and treatment of CNS 
disorders, the blood-brain barrier (BBB) is a great obstacle. Intranasal delivery of peptide 
drugs is a potential strategy to bypass the BBB. Nano-carriers for the delivery of peptide 
drugs and conjugated peptides may facilitate the use of peptides in the treatment of 
neurodegenerative diseases 82,88. 
1.3 Bioactive peptides as food ingredients 
Peptides can influence the taste of food. During the last century, peptides, along 
with amino acids, have been studied for their taste-altering and -enhancing properties. 
Investigators have characterized peptides as sour, sweet, bitter, savory, or tasteless 89. The 
example of the accidental discovery of the famous sweetener aspartame (L-Asp-L-Phe-
OMe) is remarkable in this regard 90. Later, many sweet di-, tri, and tetra- peptides were 
synthesized. Peptides with bitter taste were also identified in the same time period 91. So 
far, peptide hydrolysates from a variety of sources have been extracted and purified. 
Individual peptides for a characteristic taste have been identified, and to date, this is still 
an active topic of research 92–94. There are more than 400 different peptides in the 
BIOPEP database of plant-derived products, only from food-related sources, with 
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experimentally determined sensory stimulation 95. These peptides are very interesting to 
the industry for marketing food products with unique and enhanced tastes. 
Dietary proteins contain specific amino acid sequences that are partially released 
by the action of proteases in the gut or by the activity of microbial enzymes. Most of the 
bioactive peptides are between 3 to 20 amino acids in length and their activity depends 
on the amino acid sequence and composition 96. Taste-promoting peptides show very 
diverse composition and properties4,97. Many peptides are also used as food additives 
because of health benefits. Such bioactive peptides can produce, for example, 
antihypertensive, antithrombotic, opioid agonist or antagonist, immunomodulatory, 
anticancer, antimicrobial and antioxidant responses98,99. The market for such food 
products containing bioactive peptides is growing due to the increasing consumer 
awareness about the possible health benefits of such functional foods and nutraceuticals 
100–102.  
Antihypertensive peptides are one of the most extensively studied groups of 
bioactive peptides with many of them commercially available. These peptides inhibit 
angiotensin-converting enzyme (ACE) and renin; thus, help to maintain the normal 
blood pressure and prevent hypertension. A large number of ACE inhibitory peptides 
have been identified in snake venoms, digested food proteins, and especially milk. 
Examples are the Val-Pro-Pro and Ile-Pro-Pro tripeptides that are hypotensive and 
immunomodulatory components released by β-casein and κ-casein upon enzymatic 
digestion 103,104. Much less information is available regarding bioactive peptides that 
inhibit the angiotensinogenase activity of renin. However, a recent example is the peptide 
Ile-Arg-Leu-Ile-Ile-Val-Leu-Met-Pro-Ile-Leu-Met-Ala from the red seaweed Palmaria 
palmate. This peptide was shown to reduce the blood pressure in spontaneously 
hypertensive rats by inhibiting renin activity in vivo 105. 
Another important class of food peptides is the antioxidant peptides that reduce 
oxidative stress in the human body or prevent oxidative conversions during preparation 
and storage of foods. In the body, such peptides can prevent harmful effects of free 
radicals that are formed as a result of oxidative processes. The health benefits of 
antioxidant peptides are manifold and they can play an important role in the prevention 
and treatment of chronic degenerative diseases such cardiovascular diseases, cancer, 
rheumatoid arthritis or diabetes 106. Consequently, such peptides are attractive as food 
additives. Peptide fractions (either purified or as protein hydrolysates) with antioxidant 
activity can also be added to food products to reduce oxidative changes during storage. 
The effect has been found superior to that of synthetic antioxidants such as butylated 
hydroxytoluene (BHT) and butylated hydroxyanisole (BHA), which pose potential health 
issues 107. Antioxidant peptides can be used as food emulsifiers to reduce lipid 
peroxidation in emulsion-type food products 108. Peptides with antioxidant activity have 




from mushrooms, algae and marine species that can be incorporated in foodstuffs 106,109–
111. 
Immunomodulating peptides occurring in or derived from food components have 
been found to stimulate the proliferation of macrophages into lymphocytes and 
phagocytes, or in antibody synthesis and cytokine regulation, such as Oryzatensin 
(GYPMYPLPR) from rice albumin 112. Fermentation of milk releases ACE-inhibiting 
peptides including the αS1-immunocasokinin (TTMPLW) peptide from αs1-casein (ft194-
199) that shows immunomodulatory activity. The peptide was shown to stimulate 
phagocytosis of sheep red blood cells by murine peritoneal macrophages 113. Other 
immunopeptides from β- and κ-casein, as well as from α-lactalbumin are also mentioned 
in the literature 114. Antithrombic peptides inhibit the aggregation of platelets and 
fibrinogen activation. Casopiastrin (ft106-116), a member of κ-casein–derived 
casoplatelin peptides, inhibits the fibrinogen-binding process 115. Pepsin digests of 
human and sheep lactoferrin also inhibit thrombin-induced platelet aggregation. Such 
peptides are recommended for the prevention of thrombosis occurring in patients 
affected by coronary heart disease or other blood system diseases 116,117. Casein 
phosphopeptides can function as mineral carriers by forming soluble organophosphates. 
They serve in calcium absorption under physiological conditions and inhibit caries 
lesions via recalcification of the dental enamel, making them attractive targets for dental 
therapy 118. Recently, bioactive peptides were studied for chemoprevention, i.e. to prevent 
carcinogenesis. Anti-cancer peptides have been discussed in previous sections. The use 
of nutraceuticals as anticancer peptides to reduce the risk of cancer is being investigated 
but limited data are available from human trials 119,120. Table 4 lists some of the prominent 
peptide products marketed by the food industry. 
1.4 Cosmeceuticals (cosmetic peptides) 
Cosmeceuticals are products that are applied topically to boost the skin 
appearance. Cosmeceuticals containing biologically active ingredients are considered a 
combination of cosmetics and pharmaceuticals, imparting therapeutic, disease-fighting 
or healing properties to the skin cellular structure. These products can come in the form 
of creams, lotions, serums, and ointments 125. The cosmetic industry has been using 
peptides in cosmetic products for around 20 years owing to their anti-aging properties 
126. Nowadays, peptides are an important part of the products of this industry. The 
increasing evidence for various beneficial effects of peptides is driving the cosmetics 
industry to introduce an even larger number of peptide-based products in the market. 
Various studies have shown that peptides can perform many functions including 
modulation of cell and tissue inflammation, stimulation of collagen synthesis, control of 
angiogenesis and melanogenesis, and modulation of cell proliferation and cell migration. 
The high effectivity is also due to the penetrating ability of peptides through the upper  
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Product type Peptide sequence Bioactivity 
Ameal S 120, 
Ameal S, Evolus, 
Calpis 
Milk 
Sour Milk, Beverage, 
Tablet 








Goma Papucha Sesame Beverage LVY Antihypertensive 
StayBalance RJ Royal jelly Beverage VY, IY, IVY Antihypertensive 

























Beverage VVYP Weight management 
Remake 
CholesterolBlock 
Soy Beverage CSPHP Cholesterol-lowering 
Lactium Milk Beverage, Capsules YLGYLEQLLR Stress relief 
ProDiet F200 Milk Tablets, Capsules αS1-CN(f91-100) Stress relief 
Antistress 24 Fish Capsules NA Stress relief 

































layer of the skin and its capability to support and upregulate collagen synthesis 126,127. 
Cosmeceutical peptides are generally classified into three types based on the 
mechanisms of action: signal peptides, carrier peptides, and neurotransmitter-inhibiting 
peptides. 
Recently, there is growing interest in signal peptides which act as messengers to 
trigger fibroblasts to synthesize collagen or decrease the collagenase-mediated 
breakdown of existing collagen. This results in firmer and younger-looking skin and 
studies indicate beneficial effects on wound healing as well 128–130. Apart from enhancing 
collagen synthesis, some peptides also modulate elastin synthesis, for example, palmitoyl 
oligopeptide (palmitoyl-VGVAPG) 131. Peptides can also modulate melanin synthesis in 
melanocytes, either by stimulating or by inhibiting melanin production (for tanning or 
lightening). An example is decapeptide-12 (YRSRKYSSWY) that reduces melanogenesis 
by inhibiting tyrosinase in human melanocytes 132. Other effects may be stimulation of 
lipolysis for trimming or induction of soothing effects. Hair growth stimulation or hair 
loss prevention can be affected by peptides such as biotinoyl-Gly-His-Lys 133. 
Carrier peptides stabilize and deliver important trace elements for wound healing 
and enzymatic processes. Copper is a very important element for angiogenesis, wound 
healing, and many enzymatic processes. Peptides can be used to deliver and stabilize 
copper for these processes. Some of the copper enzymes, like lysyl oxidases, are involved 
in the synthesis of collagen and elastin, giving improved skin texture and appearance. 
Superoxidase dismutase eliminates free radicals, reducing their aging effects. 
Cytochrome c oxidase is involved in mitochondrial energy production and decreasing 
oxidation of endothelial cells and so improving blood flow to the skin. The carrier 
tripeptide GHK, which also acts as a signaling peptide, facilitates the uptake of copper by 
cells, resulting in: 1) increased levels of metalloproteinase 1 and 2 and thus contributing 
to the remodeling of aging skin; 2) stimulation of type 1 collagen and certain 
glycosaminoglycans (dermatan sulfate and heparin sulfate); 3) facilitation of the 
enzymes lysyl oxidase and superoxide dismutase, as well as of cytochrome c. The 
combined effects result in improved skin firmness and texture, and in diminished 
wrinkles, fine lines, and hyperpigmentation. 
Peptides that inhibit neurotransmitter activity are the most recent class of 
cosmeceuticals. These peptides were developed to mimic botulinum neurotoxins; they 
block acetylcholine release at the neuromuscular junction. They reduce facial muscle 
contractions, thus softening wrinkles and fine lines. Peptides may inhibit enzyme activity 
either directly or indirectly, producing cosmetic effects in both cases. This includes a 
variety of peptide mixtures from soy, rice and silk fibroin. Oligopeptide mixtures from 
rice inhibit matrix metalloproteinase. These peptides also affect human keratinocytes by 
stimulating hyaluronan synthase 2 expression 134. Soy peptides inhibit proteinases, p53 
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expression and Bax protein expression in epidermal cells that were exposed to UV-B 
irradiation 135. Table 5 lists some of the important peptides used as cosmeceuticals. 
 
Table 5. Examples of peptides used in cosmetics 
Peptide Bioactivity Commercial name 
Signal peptides 
VGVAPG 139–141 
Stimulates collagen synthesis, chemo-attracts fibroblasts 
for matrix repair, downregulates elastin expression. 
 
Palmitic acid – KVK 
142 
Binds latent TGF- and induces fully functional TFG-







Same as palmitoyl-KVK. Enhanced penetration of the 




Positive feedback effect on collagen (type I and type II) 










Supports activation of cutaneous tissue repair. Matrixyl 3000 
GHK / Palmitoyl-
GHK (also a carrier 
peptide) 148,149 
Increases collagen and glycosaminoglycans (GAG) 
production by stimulating fibroblasts. 
Biopeptide-CL 
YYRADDA 150 
Inhibits procollagen C-proteinase that cleaves C-




Activates latent transforming growth factor-beta (TGF-) 
via the peptide domain, resulting in increased collagen 




Mechanism unknown, upregulates the gene expression of 










Competes with SNAP-25 in the SNARE complex thereby 





Blocks the calcium channels by coupling to the enkephalin 




Reversible tripeptide antagonist of muscular nicotinic 










 In conclusion, peptides are very important constituents of cosmetics. They 
possess great potential for cosmetic use because of their explicit activities. Most of the 
advertised products claim to slow or even reverse skin aging. Peptides can do this in 
multiple ways, either by stimulation of collagen synthesis or through inhibition of 
neurotransmitter release, both reducing fine lines caused by facial muscles contractions 
127. Like other peptides, cosmeceutical peptides also have some caveats. Some high 
molecular weight peptides are unable to penetrate the stratum corneum, the outermost 
dead cell layer of the skin 136. Natural oligopeptides, therefore, do not easily reach their 
targets. Palmitoylation of short peptides has solved this problem to a great extent 137. 
Other factors, like peptide solubility, bioavailability, potential toxicity problems, 
biostability, biodegradability, and functional compatibility with the formulations need 
to be considered. Furthermore, most of the studies that recommend peptide additives in 
cosmetics are done in vitro, which might not always be reproduced under in vivo 
conditions 138.  
1.5 Peptide Sources 
Peptides can be obtained in a variety of ways. They can be directly isolated from 
natural sources (e.g. plants, humans, animals, insects, and other organisms like bacteria 
and fungi), be produced by recombinant synthesis, or be obtained by chemical synthesis, 
which can also be used to produce peptide libraries 1,15,18,160–163. Important examples of 
biological sources are the saliva of a lizard (Gila monster – Exenatide) and viper venom 
(Lancehead viper – Captopril). Plant or fungal toxins have also proved to be a fruitful 
source of peptides and stable peptide scaffolds that can serve as a framework to add an 
active molecule graft, for example, SFTI-1, a trypsin inhibitor from sunflower 15,164. 
Plectasin (later modified to NZ2114) was discovered from a cDNA expression library of a 
mushroom fungus (Pseudoplectania nigrella)52. The microbicidal and spermicidal 
peptide sarcotoxin Pd was isolated from rove beetles (Paederus dermatitis)165. Peptides 
have been isolated from sea creatures, such as mitomycin that was isolated from blue 
mussel Mytilus galloprovincialis 166. A whole class of lasso peptides with a variety of 
medically interesting functions, of which antimicrobial activity is the most common, has 
been identified in bacteria 167. 
The use of natural resources can be advantageous for the discovery of bioactive 
peptides. Interesting peptides can be detected directly via pharmacological screening 
and extraction from a material like an animal venom that should have bioactive 
components. Genomic information can also be useful, and a combined approach can lead 
to a specific peptide of interest 15. For example, in the CONCO project peptide XEP-018 
(a painkiller and local anesthetic) was discovered using genome mapping, transcriptome 
analysis, and proteomics of a venomous snail (http://conco.ebc.ee/) 168. Natural sources, 
however, have not proven to be economically viable for production of pure peptides in 
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large quantities. Nisin, a lantibiotic, is an exception; it is a natural fermentation product 
of Lactococcus lactis. Chemical synthesis and recombinant DNA technology are the 
methods of choice for large-scale production of peptides 169.  
Many bioactive peptide sequences occur in inactive form while embedded in the 
sequence of a larger protein. They are released from their parent molecule by proteolytic 
cleavage, e.g. during microbial fermentation of proteins or during proteolysis by 
gastrointestinal enzymes. Bioactive peptides are abundantly found in milk and dairy 
proteins where they are encrypted in the caseins or whey proteins. Consequently, they 
are also found in dairy (by-)products. In recent years bioactive peptides produced by 
marine organisms are also receiving a lot of attention, e.g. for use as nutraceuticals. 
Bioactive peptides extracted from fish, sponges, ascidians, seaweeds, and mollusks are 
potent food additives because of their antihypertensive, antioxidant, and antimicrobial 
characteristics.  
As high amounts of a bioactive peptide must be added to food to produce a desired 
biological effect, large-scale production is in demand. For industrial production in the 
food industry, microbial processes and proteolytic release from plants and microbes are 
favorable. The food industry utilizes proteolytic starter cultures and/or gastrointestinal 
enzymes to cleave whole proteins to release bioactive peptides 4. Chemical processing of 
food proteins with acid, alkali, heat and enzymatic hydrolysis can also release bioactive 
peptides 111. Peptides can also be expressed in algae as chimeric proteins, which upon 
digestion release smaller bioactive peptides 170. In addition to natural sources, peptides 
can also be designed and synthesized in a lab. Peptides designed in silico can serve as a 
huge resource for new lead peptides with better stability, bioavailability, and higher yields 
4,171. 
1.6 Limitations to peptide applicability 
As mentioned in previous sections, peptides have great potential in a wide array 
of applications. However, their use may suffer from certain disadvantages. Therapeutic 
peptides, especially AMPs, may exert undesirable toxicity in humans. Cationic AMPs 
usually target negatively charged lipopolysaccharides present in the bacterial cell 
membrane. Due to the presence of zwitterionic lipids in the human cell membranes, 
some AMPS may cross-target human cell membranes as well as extracellular surfaces 
resulting in unwanted toxicity 172. Most peptides are poorly absorbed from the gut into 
the bloodstream. Another limitation can be the low stability of peptides under 
physiological conditions 173. They are potential targets for serum proteases, which reduces 
bioavailability and in vivo stability. The structural stability can be affected by a number 
of factors such as salt and pH that may, however, hinder in vivo activity 173. Furthermore, 
the production cost at the moment is very high compared to small chemical drugs. There 




separation techniques) for large-scale downstream processing 4,174. Further studies on 
chemical modifications, use and synthesis of hybrid peptides, conjugative formulations, 
use of unnatural amino acids, and resistance to proteases are anticipated to improve the 
application potential of therapeutic peptides. In parallel, mechanisms of peptide activity 
need to be further elucidated that will help to design better peptides for improved 
absorption and pharmacokinetics and reduce the risk of undesired immune responses 
4,175. 
 
Part II. Peptide synthesis 
Many useful bioactive peptides can be obtained from natural resources. However, 
the amounts that can be isolated often do not satisfy the increasing demand of industries 
which aim to utilize peptides in commercial products. The isolation of peptides from 
natural sources often is cumbersome in terms of availability of raw material and the yield 
of the final purified peptide is insufficient in most cases 4. This drives the need for 
synthetic approaches for peptide production, and strategies that are cost-efficient and 
quick are in high demand 1. Chemical peptide synthesis can also provide structures that 
deviate from nature’s repertoire and may include molecules containing non-
proteinogenic, unnatural or chemically modified amino acids, which may be important 
for research as well as in therapeutic application. Synthetic strategies can impart 
modifications such as hydroxylation, phosphorylation, sulfation, glycosylation, and 
disulfide bond formation. It may also be used for reactions such as methylation and 
cyclisation, and for preparation of retro–inverso peptides in which the amino acid 
sequence is reversed and the α-carbon chirality of the amino acid is inverted. Preparation 
of thiopeptides and peptides with iso-peptide bonds as well as the introduction of non-
α-amino acids are also possible 2. 
Industrial production of peptides can be achieved biologically (via fermentation, 
non-ribosomal expression, and cell-free expression), chemically (solid- or solution-phase 
synthesis), or chemo-enzymatically. The size of the target peptide often determines 
which route to follow. We will elucidate these methods in detail in the next sections. 
2.1 Biosynthesis 
Fermentative peptide synthesis utilizes the natural machinery of a cell to produce 
peptides. This is the cheapest and most environment-friendly way to produce peptides 
and proteins. Fermentation is certainly the method of choice for the synthesis of large 
peptides. The major advantage is the regio- and stereo-specificity of the obtained 
product. Development of a peptide synthesis process by fermentation involves gene 
synthesis or isolation, expression of the recombinant DNA in a suitable host, cultivation, 
and downstream processing 2. Fig. 1 gives a general overview of the steps involved during 
fermentative production of a peptide via recombinant DNA technology. 
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The encoding DNA can be of many origins, either amplified from genomic DNA 
or using cDNA synthesized from mRNA, or it can be obtained by de novo chemical 
synthesis. Often, the DNA fragment needs to be codon-optimized to match the 
preference of the expression host 176. Selection of the host system is a major task. The first 
choice is most often E. coli, which in fact suffers from many drawbacks. It lacks the 
enzymatic machinery for many post-translational modifications (e.g. glycosylation) and 
efficient peptide secretion 177. It also contains endotoxins that might enter into the 
 
Fig. 1. Overview of steps for recombinant peptide/protein production 2 
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purified peptide and make it difficult for a safe application 178. To overcome these 
obstacles, eukaryotic systems like yeast and mammalian expression systems can be 
utilized 179. Such systems for fermentative peptide synthesis can produce large amounts 
of recombinant peptides but need to be optimized for every single peptide/protein and 
for each host expression system. This task is labor-intensive and becomes more 
complicated in case of larger expressed peptides. Peptides on the smaller end of the size 
spectrum tend to form insoluble particles and cellular proteases can degrade them, 
decreasing the product yield 180. It is also difficult to introduce non-proteinogenic amino 
acids into peptides 181. Peptides might not always be secreted by the expressing organism 
which often leads to complicated purification strategies 182,183. 
Even though the limitations of fermentative peptide synthesis seem daunting, 
numerous peptides of pharmacological interest have been synthesized this way. 
Historically, somatostatin is the first example of a peptide produced by recombinant 
DNA technology (1977). The DNA for this peptide hormone was chemically synthesized, 
codon optimized for E. coli, and inserted into a suitable expression plasmid as a fused 
protein with β-galactosidase to prevent degradation by cellular proteases. The peptide 
was later cleaved from β-galactosidase by the action of cyanogen bromide to release the 
mature hormone 184. About a year later, recombinant production of human insulin was 
reported. The two chains were expressed separately in two different bacterial strains and 
later joined by disulfide bonds 185. Still later, human fibroblast interferon (F-IF) was 
cloned from cDNA, which is devoid of introns common to eukaryotic systems, so 
expression in E. coli was relatively straightforward 186. Codon optimization of synthetic 
DNA was used to improve the production of INF-β 187. The production of human growth 
hormone is also worth mentioning here, as the gene could not be expressed 
straightforwardly in a bacterial system since the gene contains many introns. 
Furthermore, it contains a signal sequence needed for export out of the cell that must be 
cleaved off to release the mature hormone. Cloning and expression from cDNA initially 
gave a suboptimal peptide yield (2.4 mg/L)188. The system was later optimized by fusion 
to the E. coli ompA signal sequence, which resulted in the export of the peptide to the 
bacterial periplasm, thereby enabling disulfide bond formation 189. Similarly, interferon-
β production yield was also improved by directing the peptide to the periplasm 190. 
Production of insulin was also optimized by expressing as a fusion peptide such as 
proinsulin that was subsequently transformed into active insulin by enzymatic cleavage 
191. Other tags such as maltose-binding protein (MBP), bacterial transcription factor 
NusA, glutathione-S-transferase (GST), solubility-enhancing tag (SET), and small 
ubiquitin-related modifier (SUMO) etc. have been used to obtain better expression of 
difficult peptides as well 192. However, with high expression levels, inclusion bodies tend 
to form, reducing the activity of the peptide due to misfolding. This problem can also be 
solved in many ways. For example, by expressing peptides as concatamers, as in the case 
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of proinsulin, neuropeptide substance P, and the self-assembling peptide P11-2, which 
were later cleaved to release individual peptides 193–195. Other expression systems 
including baculovirus-infected insect cells, yeast cells, transgenic tobacco plant cells, and 
in vitro cultured tracheal epithelial cells have also been developed to express difficult 
peptides 196,197. 
2.1.1 Non-ribosomal peptide synthesis 
Another method for utilizing the microbial cell machinery to synthesize peptides 
is the use of non-ribosomal peptide synthesis (NRPS). In this approach, one utilizes 
bacterial multimeric enzyme complexes that work without mRNA and ribosomes. 
Instead, the process makes use of multifunctional modular NRP synthetases that contain 
distinct functional domains, for example, adenylation, thiolation, and condensation 
domains. The whole system for the incorporation of an amino acid is called a ‘module’. 
The connected modules serve as the template as well as the biosynthetic machinery. 
These synthetases create peptides that may have unique structural properties including 
rigidity (via cyclization or oxidative cross-linking of side chains) and high stability. The 
inclusion of D-amino acids, fatty acids, glycosylated amino acids, N-methylated amino 
acids, N/C terminally modified amino acids, and heterocyclic rings is also possible. 
Microbes use NRPSs to synthesize secondary metabolites that are often crucial to the 
organisms’ survival. Both bacteria and filamentous fungi use this machinery to produce 
antibiotics and other bioactive compounds that may be used as therapeutics. Examples 
are bacitracin, actinomycin, gramicidin S, surfactin, and precursors of β-lactam 
antibiotics 2,198,199. After successful fermentative production of the cyclic dipeptide D-FP-
diketopiperazine in the heterologous host E. coli, there has been a lot of attention toward 
utilizing this tool for peptide synthesis. Recently, antitumor peptides (echinomycin and 
triostin A) were totally synthesized utilizing a recombinant NRPS machinery in E. coli 
200. The system allows for the one-pot synthesis of complex peptides from simple carbon 
and nitrogen sources. The NRPS module can be fine-tuned for biosynthesis of novel 
peptide molecules, by swapping individual domains in the module from other NRPS 
complexes, deleting or inserting of certain modules, or by introducing mutations in a 
different domain of the module by protein engineering 201,202. In practice, however, this 
is a complicated task due to delicate interactions between the domains that must be 
maintained for proper peptide synthesis. Nevertheless, the last decade has seen notable 
progress in the engineering of novel NRP products. One bottleneck is that each 
synthetase module has to be fine-tuned for the formation of a single substrate-specific 
peptide bond. As the technologies are advancing, mutants can be generated more quickly 
and larger numbers of variants can be tested. Predictions with computational tools are 
very promising in this regard. Engineering of NRPSs thus may become increasingly 




2.1.2 Cell-free expression systems 
As mentioned earlier, production of short peptides by fermentation is 
problematic. Even after an overexpression system is developed, the desired peptide can 
aggregate and form inclusion bodies that may hamper growth or the peptide aggregates 
may be too unstable to carry on for downstream processing. For such reasons, as outlined 
above, fermentation is most promising for large peptides (50 to >100 amino acids). Many 
of the problems could potentially be avoided by using in vitro cell-free translation 
systems, which are commercially available 204. Continuous-flow cell-free systems (CFCF) 
and continuous-exchange cell-free systems (CECF) have been developed with improved 
peptide turnout 205. These systems grant addition of amino acids, ATP, and GTP 
continuously to the reaction mixture and tandem removal of the peptide product. This 
was demonstrated by producing cecropin P1 (a mammalian AMP consisting of 31 amino 
acids) fused with green fluorescent protein (GFP), albeit with low yields reported 206. 
Many modifications based on the original cell-free transcription-translation system have 
been developed, either to obtain higher yields or to increase the capacity of the system. 
Microfluidic array devices with cell-free expression of peptides have been developed and 
used for the successful synthesis of GFP and luciferase. Such a device could be applied 
for high-throughput expression, and although not suitable for large quantities, it would 
be possible to prepare arrays of different peptides in a short time. Furthermore, unnatural 
and chemically modified amino acids could be incorporated, and protein folding could 
be optimized by modification of reaction conditions 205,207. A recent example is the 
WGCFS (wheat germ cell-free expression system) that introduced high-level 
multiplexing. The system has a potential of producing tens of thousands of peptides in 
few weeks 208. 
2.2 Chemical synthesis 
Chemical synthesis is considered as the best method for the synthesis of small to 
medium-sized peptides (5 – 50 amino acids). It is by far the most mature technology for 
peptide synthesis and can be used to synthesize most possible peptide sequences, 
including many that are difficult to express in bacteria and peptides that contain 
unnatural amino acids 1,209. Chemical peptide synthesis methods generally utilize two 
general steps. First, protecting groups for amino acids are selected, along with a 
deprotection and activation reactions. Second, a peptide bond is formed between the two 
building blocks 210. The protecting groups are selected such that the amino acid side 
chains do not undergo peptide bond formation; peptide bonds are only formed between 
an amino acid (or peptide) that is protected at its amino group (or N-terminus) and an 
amino acid (or peptide) that is protected at its carboxylate group (or C-terminus). This 
prevents polymerization of the same amino acids (or peptides) after activation. After the 
coupling step, protection at the amino group is removed so that it becomes available for 
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next coupling step. When the desired peptide is synthesized, selective removal of the 
amino acid side chain protecting groups is done to obtain the final product 1. The 
protecting groups are preferably orthogonal so that the deprotection at either C or N 
termini occurs independently of each other and does not interfere with the side chain 
protecting groups, which are usually removed after the last step of synthesis 210,211. 
Chemical peptide synthesis is usually achieved via three routes i.e. solution phase peptide 
synthesis, solid-phase peptide synthesis, and a hybrid approach.  
2.2.1 Solution-phase peptide synthesis 
Solution-phase peptide synthesis (SPS) is the method of choice when the required 
peptide length is less than 15 amino acids 212. It is mostly done in a stepwise manner. An 
N-protected amino acid is coupled with a C-protected amino acid, giving an N- and C-
protected dipeptide. Depending on the strategy adopted, further coupling can be carried 
out in two ways. In case of synthesis in the N→C direction, the N-terminus is kept 
protected and C-terminus is deprotected and activated to be available for next 
condensation reaction with another C-protected amino acid. In case of synthesis in the 
C→N direction, the C-terminus would be kept protected and the N-terminus would be 
deprotected to react in the next step 213. The choice for coupling in the N→C or C→N 
direction is mainly based on the cost of the protecting groups, which must be added to 
each amino acid that needs to be incorporated and must be removed after each peptide 
bond formation step. The C-terminal protected amino acids (e.g. as carboxamide or tert-
butyl (tBu) ester) are cheaper, thus making N→C synthesis the preferred choice in most 
cases 2,214. The side-chain protecting groups are removed after the last coupling step and 
the product is purified. Fig. 2 shows a schematic representation of a solution-phase 
peptide synthesis strategy. 
Solution-phase peptide synthesis is a very flexible approach to peptide synthesis with the 
additional advantage that peptides and intermediate products can be isolated and 
purified at each step and further steps can be designed at ease 1. The process can be 
repeated in an iterative manner to expand the peptide chain, but it is also possible to 
prepare protected fragments that are coupled together to obtain large peptides. In 
principle, the process should give high yields and allow for rapid synthesis, but in 
practice, partial racemization and formation of by-products may cause problems. In 
some cases, racemization could be avoided e.g. in case of oxazolone formation during 
activation and coupling of the carboxyl group 210,215. Racemization is avoided when 
coupling involves glycine or proline. Proline resists racemization because of its ring 
structure 215. Besides the high purity of the final product, the necessary purification of 
intermediates after every coupling step can make the process considerably time-
consuming in case of long peptides. The use of protecting groups also adds to the costs 
of the process 1. The growing peptide chain, containing fully protected amino acids, tends 




slow and cause incomplete conversion resulting in by-products 216. Also, the process 
utilizes toxic organic solvents (e.g. diethyl ether, trifluoroacetic acid (TFA), hydrofluoric 
acid (HF), and hydrazoic acid), which is not environment-friendly. These phenomena 
limit the feasibility of solution-phase peptide synthesis to short peptides 1,2. 
(A) 
(B) 
Fig. 2. (A) Solution phase peptide synthesis (R = amino acid side chain, X = N-terminal 
protecting group, Y = C-terminal protecting group, P = side chain protecting group (if 
present)). (B) Examples of commonly used N-terminal and C-terminal protecting groups. 
General introduction: enzymatic synthesis of bioactive peptides 
 
2.2.2 Solid phase peptide synthesis 
Solid-phase peptide synthesis (SPPS) was introduced by Merrifield in 1963 by 
synthesizing the tetrapeptide Leu-Ala-Gly-Val 217. In SPPS, the first amino acid of the 
desired peptide chain is attached via its carboxylic acid group to a polymeric support. 
Subsequent coupling with an α-amino protected amino acid results in the formation of a 
support-bound dipeptide. In the next step, the α-amino group from the dipeptide is 
deprotected and coupled to the next protected amino acid. The coupling and 
deprotection cycle is repeated until the desired peptide chain is achieved. The desired 
peptide is obtained by removing all the protecting groups from the chain and cleaving 
the peptide from the polymeric support 1,2. Fig. 3 shows a schematic representation of 
SPPS.  
The process has many advantages compared to solution-phase peptide synthesis. 
SPSS allows the reaction systems to be automated and it excludes the issue of peptide 
solubility as the growing peptide chain is attached to a solid polymeric support. The 
process is much faster, cheaper to develop, and requires fewer solvents 212,217. It also 
excludes the necessity of tedious isolation and purification of the intermediates. 
Therefore, SPPS is the method of choice for synthesizing medium to large peptides (10 - 
50 amino acids). As the growing peptide chain stays bound to the polymeric support, the 
product can be easily obtained at the end and any by-products or excess reagents can be 
removed by filtration. The concept of solid-phase synthesis has found application in 
other fields requiring iterative synthetic steps, e.g. in oligonucleotide synthesis. 
The original SPPS protocol utilized t-butoxycarbonyl (t-Boc)/benzyl combination 
as the protecting groups. t-Boc is used for the protection of the α-amino group and the 
benzyl ester for the side chains of several amino acids. The method utilizes trifluoroacetic 
acid (TFA) and hydrofluoric acid (HF) for cleavage of N-terminal t-Boc groups and for 
side-chain deprotection, respectively. This method is still widely used for specialist 
applications. Later introduction of the alternative protecting 9-
fluorenylmethoxycarbonyl (Fmoc)/benzyl combination has increased the versatility of 
SPSS 218. Today, Fmoc SPPS is the most preferred method of choice in the industry 
because of the mild deprotection and cleavage possibilities. 
Despite its wide use, SPPS has still to achieve its full potential. Although the method has 
the advantage of using fewer reagents than solution-phase peptide synthesis, lower 
chances of racemization, and faster turnout time, there is a need for constant 
improvement of side-chain protection strategies in order to obtain pure peptide products 
that are free from any side products. Most of the reagents are costly and used in large 
excess, especially in the early stages of development at the lab scale. Inter-chain 
aggregation (hydrophobic collapse) may occur in regions where apolar interactions (e.g. 
between protected side-chains or hydrophobic groups) can lead to a gel structure, 




during purification and cause a low yield, or even give production of truncated forms of 
the target peptide 219. In such a case, peptide synthesis often cannot proceed over 10-15 
amino acids. Furthermore, after solid-phase synthesis, the peptides still have to be 
purified by HPLC, which adds to the production cost. The length limit of peptide synthe- 
 
Fig. 3. Principle of SPPS. Abbreviations: P = permanent side chain protecting group, T = 
temporary Nα-protecting group, A = activating group, X = NH or O,  = linker. 
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sis by SPPS is sequence dependent. Peptides of more than 50 amino acids have been 
synthesized successfully but a peptide of fewer than 10 residues might be impossible to 
make 220. Still, the applicability of SPPS is remarkable, with the availability of manual 
and automated systems for small and large-scale peptide synthesis of one or multiple 
peptides at the same time. 
SPPS can be carried out in three different ways, i.e. sequential synthesis, 
convergent synthesis, and chemical ligation. In sequential synthesis, amino acids are 
added stepwise until the desired peptide is obtained. This strategy is most common for 
peptides of up to 50 amino acids in length. In chemical ligation, short unprotected 
peptides that are activated in such a way that they will react chemoselectively with only 
one group from the ligation partner, resulting in the site-directed formation of a new 
native peptide bond. Chemical ligation is employed mainly for the synthesis of large 
proteins and peptides 221–223.  
2.2.3 Convergent peptide synthesis 
In convergent synthesis (or hybrid approach), peptides of up to 50 residues are 
synthesized in a sequential manner and later ligated either by a suitable solid phase or 
solution phase coupling method 224. This increases the chance of high peptide purity as 
the starting fragments are already purified and characterized and will also have 
properties very different from the desired product. Consequently, this is the preferred 
method for preparing large peptides 1,220. The drawback is that the reaction rates of the 
coupling step are considerably lower than the coupling rates of the activated amino acids 
used in stepwise synthesis, primarily due to lower solubility of peptides containing 
protected amino acids. This has been solved to some extent by using a mixture of 
solvents. Moreover, as already mentioned in case of SPS, there is a risk of racemization at 
the coupling site during fragment ligation. The problem of racemization can be avoided 
by using proline or glycine at the C-terminus of the N-terminal fragment, which is not 
always possible. In that case, ligation is performed with Ala or Arg which are less likely 
to racemize during activation 1. Both solution-phase and solid-phase variants are 
available for convergent peptide synthesis 2. Fig. 4 illustrates a typical convergent peptide 
synthesis. 
Chemical peptide synthesis is an active area of development. A great effort is going 
on to reduce the use of organic solvents and lessen the use of protecting groups 225–227. 
Solvents are being developed that reduce racemization during activation and coupling 
228. Native chemical ligation (NCL), along with its variants, has been introduced to 
overcome the limitations of SPPS for the synthesis of large peptides and to reduce the 




2.3 Chemoenzymatic peptide synthesis 
Although chemical peptide synthesis methods, especially SPPS, are mature 
strategies for making peptides, the problem of inevitable racemization during synthesis 
incurs heavy costs on the peptides because it leads to loss of expensive precursor 
fragments 1. This demands alternative strategies and the answer is the formation of 
peptide bonds with the help of enzymes. Enzymes have a clear advantage over chemical 
synthesis in the sense that the racemization never happens, as the enzymes are regio- 
and stereo-selective at the coupling positions. This characteristic allows the use of amino 
acid building blocks with minimal or no protection, cutting the costs of reagents. Since 
enzymes catalyze coupling reactions under mild conditions, the use of toxic and 
hazardous chemicals in chemical synthesis is reduced, making the process 
environmental friendly 1,2. 
An ideal option for enzymatic peptide synthesis would be the use of a universal 
C-N ligase having a high catalytic efficiency and that can couple all 21 proteinogenic 
 
Fig. 4. Convergent approach for peptide synthesis using peptide coupling of fragments 
produced by SPPS. represents an N-terminal protecting group,  represents a C-
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amino acids in every possible combination. This is not possible with enzymes obtained 
from nature 230. In a living cell, ribosomal peptidyl transferase catalyzes the stepwise 
coupling of amino acids starting from the N-terminus of the growing peptide chain. The 
use of a ribozyme for in vitro peptide bond formation has been demonstrated 231. 
However, the ribosomal peptidyl transferase is not a specific enzyme and catalyzes the 
coupling indiscreetly, irrespective of the amino acid side chain that is present. Nature 
controls the specificity with a multitude of factors including tRNA selectivity. 
Furthermore, the system requires coordinating factors that are involved in peptide chain 
elongation 232. This explains the focus on enzymes that can selectively cleave a peptide 
bond – peptidases. Peptidases (or proteases) include an enormously wide range of 
enzymes that cleave peptide bonds by hydrolysis. In principle, we can fine-tune the 
reaction conditions to trigger these enzymes to catalyze the reverse reaction 233. In fact, 
the synthetic capability of some proteases like pepsin, papain, and trypsin have since long 
been reported in the literature 234. Additionally, proteases can catalyze esterification and 
transesterification reactions. This property makes them attractive catalysts for achieving 
very diverse conversions such as the kinetic resolution of racemic alcohols and carboxylic 
acids or the synthesis of glycoconjugates 235,236. 
For the purpose of chemoenzymatic peptide synthesis, a peptidase should 
catalyze the coupling of smaller peptide fragments 233. Mechanistically, one utilizes the 
principle of microscopic reversibility of the hydrolase mechanism for the coupling amino 
acids, dipeptides, and even larger peptides 235. Typically, the enzymatic coupling 
comprises an acyl donor, which is either an amino acid or peptide that becomes the N-
terminal part of the ligation product and an amine donor (or acyl acceptor) that becomes 
the C-terminal part 233,236. In the case of protease catalyzed coupling reactions in aqueous 
media, the equilibrium of the reactions inclines toward the more stable hydrolysis 
products and synthesis yields are low. Fortunately, the conversion can be driven towards 
synthesis despite the unfavorable equilibrium by manipulating the reaction conditions, 
by product removal (e.g. precipitation), or by using an activated precursor fragment of 
which conversion to a coupled product is thermodynamically feasible 230,236. Generally, 
as explained below, the synthesis can be approached in two different ways, i.e. 
thermodynamically controlled synthesis or kinetically controlled synthesis. 
2.3.1 Thermodynamic and kinetic control of enzymatic peptide synthesis 
In case of thermodynamic control (Fig. 5), the extent of the synthesis reaction (i.e. 
the reverse of hydrolysis) depends on the position of the thermodynamic equilibrium 
under the actual reaction conditions. The enzyme itself does not affect the equilibrium 
concentrations and the synthesis and hydrolysis reactions occur at the same time. 
Equilibrium can be shifted to synthesis by using excess of one of the reactants, by 
removing the products by precipitation, complexation, or extraction, by adding organic 




groups, by using reverse micelles, or by employing anhydrous media with minimal water 
concentration. Also, the use of water mimics and optimization of the pH of the reaction 
medium may improve yields of coupling reactions 2,230. One advantage of 
thermodynamically controlled synthesis is that proteases can be used irrespective of 
their mode of action. In spite of this advantage, thermodynamically controlled reactions 
require large amounts of enzyme and the reaction rates are usually low. Often, the use of 
organic solvents to shift the equilibrium further reduces the catalytic activity of the 
enzyme 237. On the other hand, organic cosolvents also decrease the dielectric constant 
of the medium resulting in a lowering of the acidity of the carboxyl group and to some 
extent a reduction of the basicity of the amino group of the nucleophilic amino acid (or 
peptide). This increases the concentrations of non-charged species that take part in the 
coupling reaction 238.  
In kinetically controlled synthesis, an activated peptide is used that undergoes a 
peptidase-catalyzed coupling reaction with a second peptide at a much higher rate than 
hydrolysis, even in aqueous medium. Kinetically driven synthesis thus makes use of a 
high-energy C-terminally activated precursor peptide that is N-protected (Fig. 6). The 
catalyst usually is a (modified) serine or cysteine protease that is acylated by this C-
terminally activated peptide fragment. For synthesis to proceed, the acyl-enzyme 
intermediate must preferentially (kinetically) be cleaved by the nucleophilic N-terminus 
of another peptide (or amino acid) as compared to cleavage by water. In that case, the 
peptidase-catalyzed reaction produces a coupled peptide, which may undergo 
(unwanted) slow secondary hydrolysis. Thus, in kinetically controlled synthesis, the 
concentration of synthetic product reaches a maximum until upon prolonged reaction 
times the formation of the hydrolysis product becomes significant. Ultimately, the 
system would slowly proceed to the thermodynamic equilibrium. Thus, the reaction 
should be stopped once the C-terminally activated precursor peptide acting as the acyl 
donor is consumed; after that hydrolysis becomes imminent. One can improve the 
transient synthetic yields by increasing the concentration of the nucleophile, by 
modifying the reaction conditions, or by optimizing the enzyme 235. Still, the product 
must be removed at the right moment to avoid undesirable secondary hydrolysis. 
 
Fig. 5. Thermodynamically controlled chemo-enzymatic peptide synthesis based on microscopic 
reversibility of the hydrolytic reaction. 
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For kinetically controlled peptide synthesis, proteases are used that form acyl-
enzyme intermediates (Ac-E) when reacting with the C-terminally activated precursor 
230. For this purpose, serine and cysteine proteases are applied, such as subtilisin, trypsin, 
chymotrypsin, or papain. Other hydrolases than proteases, such as lipase and penicillin 
G acylase, can occasionally also be used for peptide synthesis. For synthesis to proceed, 
the formed acyl-enzyme intermediate must transfer its acyl group to the nucleophilic N-
terminal amino group (N-H) of an incoming peptide. This amino group thus must 
outcompete water to allow peptide bond formation (Ac-N bond) instead of hydrolysis 
(Ac-OH). In other words, synthesis outcompetes hydrolysis of the acyl donor, even if the 
latter is thermodynamically preferred. Not surprisingly, the newly formed peptide (Ac-
N) bond can slowly be hydrolyzed by the peptidase, again via formation of an acyl-
enzyme intermediate. Thus, the ratio of synthesis by acyl transfer to the nucleophile 
compared to the rate of hydrolysis influences the product yield, and this S/H ratio should 
be as high as possible. Occasionally, peptidases can cleave the internal peptide bonds 
present in the oligopeptides that are used for the coupling reaction. Such side reactions 
occur due to the broad specificity of serine and cysteine proteases and can lead side 
products.  
As illustrated in Fig. 7, kinetically controlled peptide coupling can happen at a 
high rate and give much higher yields as compared to thermodynamically controlled 
coupling. This is especially true in the initial phase of the reaction. As the maximum yield 
is reached, hydrolysis ensues and if the reaction is allowed to continue, the yield will 
decrease and the system will slowly approach the thermodynamic equilibrium. 
 




Usually, the acyl donor (N-terminal fragment in the coupled product) is provided 
as a peptide of which the carboxylate group is activated in the form of an ester 236. In the 
beginning of a conversion, this allows rapid formation of an acyl-enzyme and the yield 
of the synthetic product depends on the apparent ratio of the transferase: hydrolase rate 
constants. As conversion proceeds and product accumulates, the affinity of the enzyme 
for the activated acyl donor compared to the affinity for the coupled product becomes 
important, another reason why esters are attractive acyl donors. These enzyme-related 
kinetic features explain the large differences between different enzymes with respect to 
synthetic yield that can be obtained. Still, with most enzymes, the reaction must be 
terminated as soon as the acyl donor is consumed since otherwise, hydrolysis of the 
product can commence. 
Kinetically controlled synthesis is affected by pH and ionic strength. The 
nucleophile that attacks the acyl-enzyme complex (Fig. 6) must be uncharged, so a high 
pH is desirable. The optimum pH is usually close to the pKa of the amino function of the 
nucleophile. The presence of organic solvents can help to dissolve the activated esters 
and also reduce the chances of hydrolysis of the ester or the peptide product. The 
specificity of the enzyme has a strong effect on the efficiency of kinetically controlled 
conversions and finding a good match between enzyme properties, peptide sequence at 
the coupling site, and nature of the activation group is of key importance.  
As with chemical synthesis, chemoenzymatic peptide synthesis can be carried out 
by N- or by C-terminal extension 239. In case of N-terminal extension, i.e. C→N enzymatic 
peptide synthesis, the C-terminus stays permanently protected and the amine of the 
growing peptide chain acts as the acyl acceptor (nucleophile). In this strategy, each amino 
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acid that is to be added must be N-protected to prevent self-condensation, and this N-
terminal protecting group must be removed after each coupling step. This makes it a 
costly process because N-protection groups are expensive. In contrast, in case of C-
terminal extension, i.e. N→C peptide synthesis, the N-terminus of the growing chain is 
permanently protected and at each step, an excess of a C-terminally protected (or non-
activated) amino acid building block is used as the nucleophilic acyl acceptor. This 
strategy requires selective C-protection and deprotection (or activation) before the next 
coupling step. Synthesis of peptides with a protected or activated C-terminus can be 
achieved easily, for example via synthesis of carboxamides, which are cheap protection 
groups. The acyl group can be activated, for example in the form of alkyl esters, to 
increase the efficiency of nucleophilic attack by the amino group. Such a strategy would 
require additional, preferably enzymatic, procedures for modifying the C-terminus. 
Esterases, lipases, proteases, and amidases are good candidates for C-terminal 
esterification of amino acids 240–242. In principle, both strategies require little to no side 
chain protection of amino acids owing to the selectivity of the proteases. 
 
Part III. Peptide modification 
3.1 Enzymatic peptide terminal modifications: 
Peptide synthesis commonly utilizes protection and deprotection steps of the 
building blocks for controlled synthesis with avoidance of self-coupling reactions. 
Orthogonality of protecting groups is very important in order to protect and deprotect 
different functional groups independently of one another. In chemical synthetic routes, 
not only C-terminal and N-terminal protection but also side chain protection needs to 
be considered 243. The use of enzymatic methods for protection, deprotection, and 
terminal modification has several advantages compared to chemical modification, owing 
to the possibility to use milder reaction conditions and by offering a selectivity that is 
superior in comparison to chemical methods 244. In case of enzymatic reactions, side-
chain protection is not required because of the enzyme’s selectivity for the terminal 
functional groups of the main chain 1. Several enzymatic methods for peptide or amino 
acid protection and deprotection reactions have been explored, as discussed below. 
3.1.1 Nα-terminal modifications 
Nα-amino groups can be blocked reversibly by acylation, alkylation, and alkyl-
acylation and a large variety of amino-protecting groups has been described 245. It is 
desirable that the protecting group should be removable under mild conditions to 
prevent the peptide from exposure to extremely acidic or basic conditions. A variety of 
alkoxycarbonyl-type (carbamates or urethane-type) N-protecting groups is available that 




tert-butoxycarbonyl (Boc), and 9-fluorenylmethoxycarbonyl (Fmoc) are commonly 
used. Boc and Fmoc are often used for N-protection in SPPS in Boc/benzyl (Bn) and 
Fmoc/tert-butyl (tBu) strategies, respectively. The Z-group is often utilized in solution 
phase synthesis 211. These groups are introduced by reacting the amino group with 
chloroformates or carbonic acid derivatives or mixed carbonate esters. Deprotection can 
be achieved by various methods e.g. hydrogenolysis in case of Z-group, protonolysis in 
case of Boc-group and β-elimination in case of Fmoc-group 245. The groups are indeed 
employed under relatively mild conditions but there is a chance of dipeptide formation 
during the synthesis of N-protected amino acids due to the interference by the free α-
carboxyl group. Hence, there is an ongoing search for protecting groups that can be 
cleaved off by enzymes. Such enzymatically cleavable protecting groups can be useful for 
the construction and manipulation of larger peptide units that need to be reacted under 
aqueous conditions, mainly for solubility reasons, but also in case of fragile peptide 
chains 2,244. Moreover, an enzymatic procedure would be devoid of racemization and may 
be more cost-effective. 
Initial attempts to introduce an enzyme-labile amino protecting group date back 
to 1955 when chymotrypsin was used for the removal of Bz-Phe (N-
benzoylphenylalanine) from the tripeptide Bz-Phe-Leu-Leu-OH to obtain the H-Leu-
Leu-OH dipeptide 246. However, being an endopeptidase, the risk of peptide cleavage 
limits the applicability of chymotrypsin for this purpose. Later, trypsin, which has a 
narrower substrate specificity (i.e. only hydrolysis of Lys-X and Arg-X peptide bonds), 
was employed for the removal of Z-Arg as N-terminal protecting group. Z-Arg was 
coupled chemically with amino acid nitrophenyl esters to yield Z-Arg-aminoacylates (Z-
Arg-X-ONp) that were further coupled chemically to peptide amides resulting in Z-Arg-
protected peptides. At the last step of synthesis, trypsin was used to cleave the N-terminal 
Z-Arg yielding the final peptide product (Fig. 8) 247. The method did not find general 
applicability owing to the difficult preparation of p-nitrophenyl esters. Nevertheless, it 
was utilized for the synthesis of oligo- and polypeptides via condensation of pre-formed 
peptide fragments, for instance in the preparation of β-lipotropin, oxypressin, Met-
enkephalin and Glu-oxytocin 244. 
The use of the above-mentioned proteases for N-terminal modification is 
accompanied by a risk of peptide bond cleavage at undesired internal sites in the peptide 
backbone. In principle, this risk can be overcome by using an enzyme that is not active 
as a protease in nature. Penicillin G acylase has been explored in this regard as the 
enzyme cleaves off phenylacetic acid (PhAc) from N-phenylacetyl peptides without 
hydrolyzing internal peptide bonds 248. The enzyme has been used to synthesize 
phenylacetyl derivatives of amino acid esters and peptides, and for deprotection of the 
N-phenylacetyl peptides 244. Immobilized penicillin acylase was used to selectively 
remove the phenylacetyl group from the N-phenylacetyl-aspartame to obtain aspartame 
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as the final product 249. Later, the enzyme was used for the formation of N-phenylacetyl 
protected amino acid esters, dipeptides, and tripeptides 250. A fully enzymatic synthesis 
of leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu-t-butyl ester) has been described where 
penicillin acylase catalyzed both the N-PhAc-amino protection and deprotection steps 
(Fig. 9) 251. Another enzyme, phthalyl amidase, was found to deprotect a variety of N-
phthalimido substrates after the substrates were first partially hydrolyzed by weak base 
to their monoacids (Fig. 10) 252. 
The benzyloxycarbonyl group (Cbz- or Z-group) has also been studied for 
enzymatic deprotection of N-terminally protected amino acids. The first example of a 
urethane hydrolyzing enzyme was reported in 1985 and it was named urethane hydrolase 
I 253. However, the enzyme had a narrow substrate range and hydrolyzed only Z-Gly-OH 
efficiently. Moreover, a free carboxylate functional group was needed and a modification 
at the C-terminal end inhibited the enzyme activity. The same group of researchers 
identified similar enzymes, urethane hydrolases II, III and IV. All the enzymes exhibited 
narrow substrate specificity and accepted only Z-protected L-amino acids 254–257. Of these 
four enzymes, urethane hydrolase IV exhibited the better substrate range, accepting Z-
Leu, Z-Gly, Z-Ala, and Z-Ser as good substrates. In the same study, urethane hydrolase IV 
also deprotected Boc-protected amino acids, which is the only reported case of an 
enzymatic Boc deprotection 257. Still, this proved to be inefficient for broader synthetic 
applicability 244. 
 
Fig. 8. Scheme for synthesis of a hexapeptide utilizing Z-Arg as the N-terminal protecting 
group 247. X = L-Glu, D-Glu, L-Ile or L-Tyr; Y = HCl, HBr or toluenesulfonic acid; DCCI = 
dicyclohexylcarbodiimide. 
Z-Arg-OH·HCl + H-X-ONp·Y 
Z-Arg-X-ONp·Y 










 Recently, urethane hydrolases have been reported that show broader substrate 
range. A urethane hydrolase from Arthrobacter species was found to remove the N-
terminal Z-group from a variety of N-protected amino acids and related compounds. Like 
other urethane hydrolases, this enzyme required a free α-carboxylic acid group 258. A 
urethane hydrolase from Sphingomonas paucimobilis has been reported that selectively 
cleaves Z-protected L-amino acids 259,260. Another urethane hydrolase from Burkholderia 
phenazinium was reported by the same researchers to selectively hydrolyze Z-protected 
D-amino acids. Although both enzymes exhibit wider substrate range than previously 
reported for urethane hydrolases, the substrate range is still restricted to single amino 
acid substrates. Moreover, unlike previously reported urethane hydrolases, these 
enzymes show no requirement for a free α-carboxy terminal. While they have no 
demonstrated use in peptide synthesis, these enzymes are presumably applicable for 
enantiomeric resolution of racemic mixtures of Z-protected amino acids (Fig. 11) 261,262. 
Penicillin G acylase, mentioned above to remove N-terminal phenylacetyl groups, 
can also catalyze deprotection of the Z-protected amino acids and peptides. Immobilized 
enzyme converted a variety of Z-protected amino acids and peptides including some 
dipeptides and tripeptides into corresponding unprotected peptides. Under the 
conditions used, conversion of the C-terminal methyl- or ethyl esters of N-terminally Z-
protected substrates resulted in fully unprotected products owing to the saponification 
of ester moieties which took place before enzymatic N-deprotection under weak basic 
conditions 263. This is disadvantageous as many peptide synthesis procedures use C-
terminally esterified amino acids and peptides, which limits the applicability of penicillin 
acylase for N-deprotection of Z-groups. Other derivatives of the Z-group have also been 
developed and investigated for enzymatic deprotection. These include p-
 
Fig. 9. Penicillin acylase catalyzed synthesis of N-phenylacetyl amino acids or peptides. 
X = amino acid, dipeptide, or tripeptide 249,250. 
  
   
Fig. 10. Phthalylamidase catalyzed removal of the N-phthalyl protecting group 252. 
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acetoxybenzyloxycarbonyl (AcOZ) and p-phenylacetoxybenzyloxycarbonyl (PhAcOZ) 
groups. The AcOZ- or PhAcOZ- protected amino acids can be obtained easily from N,O-
bis(trimethylsilyl) amino acids and p-acetoxybenzyl chloroformate or p-
phenylacetoxybenzyl chloroformate respectively 264. Both AcOZ and PhAcOZ protecting 
groups include a spacer between the urethane group and the enzyme labile bond so that 
the enzyme labile bond is away from the target amino acid or peptide (Fig. 12). Cleavage 
of that bond causes the formation of a labile product that undergoes cleavage to yield the 
peptide with free N-terminus. This makes the urethane protecting group generally 
applicable as the target bond to be cleaved can be independent of the amino acid 
sequence and devoid of any steric hindrance due to amino acid or peptide structure. 
Moreover, unnatural amino acids could be used. 265–267. For deprotection of AcOZ-
peptides, acetyl esterase was used, but a lipase can also be applied for this purpose. For 
deprotection of PhAcOZ-peptides, penicillin G acylase was used due to its specificity for 
the phenylacetyl moiety. These protecting groups have been employed in the 
chemoenzymatic synthesis of S-palmitoylated and S-farnesylated C-terminus 
lipopeptides of the human N-Ras protein 265,268. 
Other urethane derivatives like tetra-O-benzyl-D-glucopyranosyloxycarbonyl 
(BGloc), tetra-O-acetyl-D-glucopyranosyloxycarbonyl (AGloc), and tetra-O-acetyl-β-D-
galactopyranosyloxycarbonyl (AGaloc) groups have been designed and studied for 
enzymatic removal. BGloc-protected amino acids are synthesized by reacting 2,3,4,6-
tetrabenzylglucose with isocyanates (of respective amino acid allyl esters) followed by C-
terminal allyl ester cleavage 269,270. The removal of the N-protecting group occurs in two 
steps. First, the hydroxyl blocking group (the benzyl ether function) is removed by 
hydrogenation, followed by treatment with a glucosidase (in case of AGloc and BGloc) or 
a galactosidase (in case of AGaloc) (Fig. 13). Apart from enzyme lability under mild 
conditions, these protecting groups have the advantage of conferring solubility to the N-
 




protected substrates. Moreover, these groups can be applied almost independently of the 
amino acid or peptides, in a manner similar to the spacer-containing urethanes, as the 
glycosidic C-O bond cleaved by the enzymes is not directly linked to the urethane 244. 
The formyl group (For-) was studied for N-terminal protection because of its low 
cost, better solubility of the protected peptides in aqueous media, ease of introduction, 
and facile removal 271. The N-formyl amino acids can be easily prepared chemically by 
reaction with formic acid in the presence of acetic anhydride and hydrolyzed by acid 
treatment (e.g. excess HCl in methanol) 272,273. The latter treatment has the tendency to 
hydrolyze internal peptide bonds. Recently, peptide deformylases (PDFs) were used to 
remove the N-formyl group under mild conditions. During ribosomal protein synthesis, 
PDFs remove the formyl group from the first methionine of the nascent peptide chains 
274. The enzyme was examined in an improved strategy to produce aspartame from For-
Asp and Phe-OMe monomers. Deprotection of For-α-Asp-Phe-OMe dipeptide (and its 
β-isomer) was performed by peptide deformylase (Fig. 14) 275. In another example, an 
engineered PDF (EcPDF) was used in the synthesis of N-formyl-Tyr-Leu-Phe-NH2. The 
strategy used thermolysin-catalyzed coupling of For-Leu with Phe-NH2. The resultant 
dipeptide was deprotected at the N-terminus with EcPDF and used for subsequent 
 
Fig. 12. Enzymatic cleavage of spacer-based protecting groups AcOZ and PhAcOZ. Acetyl 
esterase (NaCl buffer, pH 7, 45oC) was used in case of AcOZ while PhAcOZ was cleaved by 
penicillin G acylase (phosphate buffer, pH 7.5, 25oC, NaHSO3) 244. 
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thermolysin-catalyzed coupling with For-Tyr, yielding the final tripeptide 276. Studies 
show that the enzyme has a narrow substrate specificity and prefers formyl peptides with 
an N-terminal methionine. This limits the general applicability of peptide deformylase 
for chemoenzymatic peptide synthesis. Nevertheless, this does provide a platform for 
engineering PDFs and related enzymes with broader substrate specific and general 
applicability in peptide synthesis 277. 
3.1.2  Cα-terminal modifications 
In a usual SPPS synthesis, which occurs in the C→N direction, the first N-
protected amino acid is anchored to a solid support resin via an ester or amide bond 
formed between the carboxyl group and the hydroxyl (or chloro) or amino function of 
the resin. This linkage is cleaved after the last step to remove the synthetic peptide from 
the resin. This implies that after each coupling step, the growing chain is subjected to N-
deprotection such that the peptide is available for next coupling step (section 2.2.2, Fig. 
2). Consequently, most research has been dedicated towards synthesis and removal of N-
terminal protecting groups 2,243. In a reverse N→C strategy either in solution phase 
synthesis or chemoenzymatic synthesis, a carboxyl protecting group would be required. 
The most common form of C-terminal modifications relevant to peptide synthesis is 
esterification 214. A variety of protocols is available for esterification of amino acids at the 
carboxyl end. For example, methyl esters can be easily obtained by reacting amino acids 
 
 
Fig. 13. Two step enzymatic cleavage of carbohydrate based protecting groups BGloc, AGloc, 




either with hot methanolic hydrochloric acid, or with methanol and thionyl chloride 
214,240. Methyl, ethyl, benzyl, t-butyl, phenyl, and phenacyl esters have been used in this 
regard and they can be cleaved by mild alkaline (methyl and ethyl) or acidic (t-butyl) 
hydrolysis or by hydrogenation (benzyl) 2,278. 
The preference for an enzymatic route for C-terminal modification is based on the 
same arguments as stated in case of N-terminal modifications (section 3.1.1). Below we 
will discuss some important C-terminal enzymatic peptide modifications relevant to 
chemoenzymatic peptide synthesis. 
3.1.2.1 Esterification  
Esterase activity of chymotrypsin has been exploited to synthesize amino acid 
esters. Initially, chymotrypsin (immobilized on polyacrylamide or carboxymethyl 
cellulose) was used at low water concentration (20% water in alcohol) to synthesize N-
acetyltyrosine ethyl ester. The synthetic yield, however, was low i.e. 40% 279. To improve 
the yields, chymotrypsin was later employed in water: organic biphasic systems. 
Chymotrypsin was used in high ethanol concentrations to form ethyl esters of N-
acetyltryptophan and N-acetyltyrosine in water: alcohol (single phase) and alcohol: 
chloroform (biphasic system), with higher yields reported for the biphasic system 280. 
Chymotrypsin immobilized on porous glass was used to synthesize N-acetyltryptophan 
ethyl ester from N-acetyl tryptophan and ethyl alcohol in a water: chloroform biphasic 
system 281. Chymotrypsin immobilized on silica gel was used to synthesize N-
benzoylphenylalanine ethyl ester in biphasic systems using chloroform, benzene, carbon 
tetrachloride, or diethyl ether as organic solvents 282. Silica-immobilized chymotrypsin 
 
Fig. 14. Aspartame synthesis using peptide deformylase for selective deprotection of formyl 
amino acids. MES = 2-(N-morpholino)-ethanesulphonic acid. The enzymatic deprotection 








For--Asp-Phe-OMe  ( 75:25 ratio) 
-Asp-Phe-OMe   +  For--Asp-Phe-OMe 
MES/KOH buffer 
pH = 6.2 
Peptide deformylase 
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was also used to synthesize N-acetyltyrosine ethyl ester in a water: chloroform system 283. 
In another example, agarose-immobilized chymotrypsin was used to convert N-
acetyltryptophan to either the corresponding ethyl ester or to the phenylethyl ester by 
using 3-pentanone or 1,1,1,-trichloroethane as organic solvent, respectively 284. 
Chymotrypsin immobilized on poly(vinyl alcohol) was used to convert N-acetyltyrosine 
to corresponding ethyl ester, in a hydrophilic organic solvent such as acetonitrile or 
ethanol. In these experiments, the esterase activity of chymotrypsin was reversed by 
either keeping extremely low amounts of water in the system or by continuously 
extracting the ester product into the organic phase. Free chymotrypsin was later used to 
esterify N-acetyltyrosine with a number of primary alcohols in different water miscible 
and immiscible organic solvents, with best conversation rates reported for the synthesis 
of N-acetyltyrosine methyl ester in acetone 285. In another study, chymotrypsin 
immobilized on Chitopearl (porous chitosan beads) was utilized in a variety of organic 
solvents to synthesize N-acetyl-tyrosine ethyl esters. High esterification activities were 
reported with polar organic solvents (with the exception of methanol and DMF) while 
negligible esterification was observed in organic solvents such as chloroform and toluene 
286. Recently, free chymotrypsin was used to convert N-acetylphenylalanine to the 
corresponding ethyl ester in a hydrophilic ionic liquid medium (1-ethyl-3-
methylimidazolium trifluoromethanesulfonate, [emim][Tf]) 287. Although high 
conversion rates of up to 100% were reported in these studies, there is no wide 
application of chymotrypsin in esterification of amino acids or peptides within the 
context of peptide synthesis, probably due to the narrow substrate specificity of 
chymotrypsin, a property inherent to serine proteases. 
Concurrent to the esterification studies with chymotrypsin mentioned above, 
papain was also studied for esterification because of its wider substrate range compared 
to chymotrypsin. Papain was used to convert a variety of N-terminally Boc-protected 
amino acids to the respective ethyl- and benzyl esters in a biphasic system 288. Later, N-
Boc-alanine was converted to a variety of esters using primary alcohols and diols in 
dichloromethane as the organic solvent. Allyl and cyanoethyl esters were also 
synthesized 289. Synthetic yields were improved by immobilizing papain on XAD-57 and 
Sepharose for the synthesis of N-Boc-alanine and N-Boc-aspartic acid 290. Immobilized 
papain was used in ethyl acetate as the organic solvent for the conversion of a variety of 
amino acids with different N-terminal protecting groups (Z, Boc, and 
methoxybenzyloxycarbonyl groups) to methyl, ethyl, benzyl, and butyl esters 291. In 
another study, papain immobilized on Sephadex G-50 was used in 95% methanol to 
convert N-protected amino acids into the respective methyl esters 292. Immobilized 
papain (on XAD-7 resin) also converted N-Boc-dipeptides to N-Boc-dipeptide ethyl 
esters in dichloromethane as organic solvent. It was observed that a hydrophobic amino 




Formation of N-terminally Z-protected dipeptides was also catalyzed by papain 
(immobilized on Amberlite XAD-8) in ethanol containing 2% water 294. Z-alanine-sec-
phenethyl esters have also been synthesized by using Celite-immobilized papain from Z-
alanine and 2-phenethyl alcohol, with and without organic solvents 295. Amino acid 
glyceryl esters were also prepared by using papain. A variety of Boc- and Z- protected 
amino acids were converted to their respective glyceryl esters, which could be utilized in 
peptide coupling catalyzed by trypsin. Glyceryl esters of dipeptides were also synthesized 
in the same study, but with lower yields owing to secondary hydrolysis. Fig. 15 depicts a 
representative example of this synthesis 296. 
Trypsin has also been studied to perform esterification, although not much data 
is available for direct esterification reactions catalyzed by trypsin as compared to its use 
in peptide synthesis. Trypsin was investigated to esterify N-acetyl-arginine with a variety 
of alcohols in different organic solvents. The highest yields obtained were for N-acetyl-
 
Fig. 15. Formation of Z-Alanine glyceryl ester by papain and peptide coupling catalyzed by 
trypsin. Two structures of glyceryl esters are possible on esterification. Similar scheme was 
used to synthesize Z-Phe-OGl, Z-Ser-OGl, and Z-Thr-OGl esters and used for coupling via 
trypsin 296. 
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arginine ethyl ester in acetonitrile 297. In another example, polyvinyl alcohol-
immobilized trypsin was used to synthesize N-benzoyl-DL-arginine esters in hydrophilic 
organic solvents. Ethyl, 1-propyl, and 1-butyl esters were synthesized with highest yields 
reported for benzoyl-arginine ethyl ester 298. 
Another protease examined for its use in esterification reactions of amino acids 
and peptides is subtilisin. In the same study where chymotrypsin was used for 
esterification of N- acetyl-tyrosine, subtilisin Carlsberg (also called as Subtilisin A or 
Alcalase) was tested for C-terminal esterification 279. The enzyme was used in low water 
concentrations where chymotrypsin was ineffective. Maximum rates were observed in 5-
15% (v/v) of water present in media containing ethanol:glycerol (1:1) as a cosolvent 
mixture, at pH 7.6 and room temperature (≈47% yield). In contrast to immobilized 
chymotrypsin, no conversion was observed when subtilisin was immobilized on different 
support media (carboxymethyl cellulose, aminoethyl cellulose, styrene-benzoate 
copolymer, ethylene-maleic anhydride copolymer). In a later study, subtilisin Carlsberg 
was used to convert N-acetyl-tyrosine in either ethanol, 1-propanol, 2-propanol, 1-
butanol or 2-butanol to yield corresponding C-terminal esters. Maximum yields were 
reported for ethyl ester formation (90%) in presence of 2% (v/v) water in the reaction 
mixture 299. Subtilisin BPN’ was also used for esterification of N-acetyl-tyrosine. Unlike 
subtilisin Carlsberg, this enzyme was inactive in ethanol but activity was found when it 
was coupled to polyvinyl alcohol and reactions were done in the presence of added 
polysaccharides such as chitin or chitosan 299. 
Celite-immobilized Alcalase was used to synthesize Z-Tyr-sec-butyl ester, Z-Tyr-
sec-phenethyl ester, and Z-Ala-sec-phenethyl ester from their corresponding Z-amino 
acids and pure 2-butanol or 2-phenethyl alcohol used as organic solvent as well as the 
reactant 295. Free subtilisin was used to synthesize esters of a variety of N-terminally Boc-
protected amino acids and unprotected peptides after solubilizing in high amounts of 
1,3-propanediol or 1,4-butanediol at low water content. High yields of diol-mono esters 
were reported in this case. The amino acid esters were further used in enzymatic 
fragment coupling by different proteases (Fig. 16) 300. Recently, Nuijens et al. investigated 
Alcalase-CLEA to catalyze tert-butyl ester formation in neat tert-butyl alcohol as the 
solvent. High yields of N-protected-peptide-tert-butyl esters were obtained without any 
hydrolysis of the peptide when water was continuously removed from the reaction 
mixture. Most of the peptides were well accepted as substrates but amino acids with a 
tertiary β-carbon (e.g. threonine, isoleucine, and valine) were not accepted as good 






Transesterification was investigated initially in a comparative study of subtilisin 
Carlsberg, subtilisin BPN’ and α-chymotrypsin, for esterification of N-acetyl-tyrosine. 
Both subtilisin Carlsberg and immobilized subtilisin BPN’ were found to be superior 
compared to α-chymotrypsin for the synthesis of N-acetyl-tyrosine ethyl ester in ethanol 
containing 4.8% water, at 30oC (83% yield)299. In an extension of the same study, 
subtilisin Carlsberg, subtilisin BPN’ and chymotrypsin were immobilized on Chitopearl 
(porous chitosan beads). The immobilized enzymes exhibited better reaction rates than 
free enzymes for transesterification of N-acetyl-tyrosine-OMe to Na-acetyl-tyrosine-OEt 
using ethanol with a water content as low as 2.9% in the reaction mixture 286. α-
Chymotrypsin was also used to synthesize tyrosine glyceryl esters by transesterification 
from tyrosine-methyl ester using 60% (v/v) glycerol in water as reaction medium, at pH 
7 and 40oC, with a high yield (80%) 302. 
Transesterification using α-chymotrypsin has been investigated in ionic liquid 
media, primarily to minimize the destructive effects of water-miscible organic solvents 
such as alcohols 303. An example is the synthesis of N-acetyl-tyrosine propyl ester in ionic 
liquid media. Transformation occurred in a kinetically controlled process in which the 
 
Fig. 16. Subtilisin catalyzed esterification of Boc-protected peptides and unprotected 
peptides and their subsequent use in enzymatic fragment ligation 300. 
 
Fig. 17. Alcalase-CLEA catalyzed esterification of N-terminally Z-amino acids to respective t-
butyl, methyl, benzyl esters. The protocol was also used to synthesize allyl and 2-
(trimethylsilyl)-ethyl esters of Z-, Boc-, or Fmoc-protected aspartic acid and glutamic acid 301. 
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nucleophile competes with water to achieve esterification instead of hydrolysis. Ester 
synthesis was optimized by minimizing water content and by addition of triethylamine. 
A variety of ionic media were tested, of which [Bmim+][BF4-] gave best yields (Fig. 18) 304. 
Recently, both subtilisin and α-chymotrypsin, immobilized on chitosan, were used to 
synthesize N-acetyl-phenylalanine-propyl esters from the corresponding ethyl esters. 
Transesterification was performed in ether-functionalized hydrophobic ionic liquid 
media ([Me(OEt)3-Et3N][Tf2N], [Me(OEt)3-Et-Im][Tf2N], and [Me(OEt)3-Me-Et-
Im][Tf2N]) containing 1-propanol, 10-15% water, at 50oC 305. Ionic liquids are gaining 
interest in chemical synthesis procedures as well as enzymatic synthesis due to their 
nonvolatile nature, thermal stability, and low environmental impact. However, future 
work is required to make a fully enzymatic synthesis feasible in pure ionic liquid media. 
 Transesterification was accidentally observed during peptide synthesis catalyzed 
by Alcalase-CLEA by Nuijens et al. During enzymatic coupling of Z-Phe-OMe and Leu-
Ot-Bu in tert-butanol as solvent, Z-Phe-Ot-Bu was obtained as a byproduct 301. The 
discovery was interesting as chemical synthesis of tert-butyl esters is rather laborious and 
requires harsh conditions 306. Consequently, transesterification was investigated for the 
conversion of various peptide tert-butyl esters (obtained via SPPS) to methyl, ethyl, or 
benzyl esters in anhydrous media (Fig. 19). The esters served as acyl donors for the 
subsequent enzymatic coupling step. The strategy was successfully used to synthesize 
anti-inflammatory peptides (For-Met-Leu-Phe-OMe and Boc-Phe-Leu-Phe-Leu-Phe-
OH). The multistep synthesis scheme included Alcalase-CLEA catalyzed formation of 
methyl ester, initial coupling reactions, transesterification of tert-butyl esters to methyl 
esters, a second coupling, and hydrolysis to the final product. Similarly, the thermolysin 
 
Fig. 18. Transesterification of N-acetyl-tyrosine ethyl ester to N-acetyl-tyrosine-propyl ester. 
Transesterification occurred in different ionic liquids: [Emim+][BF4-], [Emim+][Tf2N-], 
[Bmim+][BF4-], [BMIm+][PF6-], [MTOA+][TF2N-]. Reactions were performed at 50oC, with 2% 





tripeptide assay product, Cbz-Phe-Leu-Ala-OH, was synthesized by initial coupling and 
later hydrolysis of the peptide to obtain the product 242. 
In order to facilitate peptide synthesis with sterically demanding and non-
proteinogenic acyl donors, and poor nucleophiles, carboxyamidomethyl (Cam) and 
trifluoroethyl (Tfe) esters were synthesized using the same Alcalase-CLEA. Cam and Tfe 
ester syntheses were also catalyzed by CalB lipase. High yields are reported for both 
enzymes, and esterification and peptide bond formation could be catalyzed in the same 
reaction mixture by using CalB and Alcalase-CLEA simultaneously (Fig. 20) 241. 
Another C-terminal modification is the formation of peptide thioesters. Peptide- 
and amino acid thioesters are important building blocks for native chemical ligation in 
peptide synthesis and macrolactamization of peptides 307,308. Peptide thioesters can be 
synthesized chemically, for example by solid phase synthesis, but the subsequent 
removal of protecting groups requires harsh conditions 309. Enzymatic synthesis of 
peptide esters is favorable as reactions would be possible under mild conditions. 
Subtiligase (a subtilisin BPN’ variant with the Ser221Cys and Pro225Ala mutations which 
 
Fig. 19. Transesterification of Z-Phe-O-tBu catalyzed by Alcalase-CLEA into primary alkyl esters. 
The procedure was also successfully applied to convert dipeptides, for example, Z-Phe-Leu-O-
tBu, Z-Ala-Leu-O-tBu, Z-Ala-Phe-O-tBu, and Z-Gly-Phe-O-tBu, to activated esters 242.  
 
Fig. 20. Cam and Tfe ester syntheses catalyzed by CalB (lipase from Candida antarctica) or 
Alcalase-CLEA 241. 
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improve synthetic performance) has been used for transesterification of peptide 
glycolate esters to peptide thioesters in the presence of N-acetylcysteamine as thiol 310. 
Quaedflieg et al. used subtilisin in a neat organic solvent for the transesterification of N-
terminally protected peptide esters by a variety of thiols (e.g. benzyl mercaptan or 3-
mercaptopropionic acid ethylester) to obtain the corresponding peptide thioesters 311. 
3.1.2.3 De-esterification 
Initial attempts to enzymatically deprotect carboxyl groups focused on the use of 
chymotrypsin, trypsin, and thermolysin. The esterase activity of chymotrypsin and 
trypsin have been investigated for hydrolysis of several peptide methyl, ethyl, and tert-
butyl esters. The investigations reported successful transformations not only with 
peptides having enzyme specific amino acids at the C-terminus but also with different 
ones. However, cleavage of internal peptide bonds was imminent in cases where trypsin- 
or chymotrypsin-labile sequences were present in the peptide. Moreover, many peptides 
were poor substrates or were not accepted at all 244,312,313. Thermolysin was explored to 
selectively cleave Leu-Gly-Gly-OEt from undecapeptide ester (Boc-Gln-Thr-Lys-His-Pro-
Lys-Lys-Gly-Leu-Gly-Gly-OEt). The tripeptide served as a supporting peptide in the 
synthesis strategy and the resulting octapeptide consisted of hydrophilic residues 314. The 
idea did not find general applicability due to the broad substrate range of thermolysin 
that poses a huge risk of internal peptide cleavage. Moreover, the enzyme was restricted 
to the use of the specific tripeptide ester (Leu-Gly-Gly-OEt) for enzymatic deprotection 
244,314.  
The problem of endopeptidase activity of enzymes could be reduced by using 
carboxypeptidase Y (CPY). The enzyme has both peptidase and esterase activities but at 
different optimum pHs. Carboxypeptidase Y (immobilized on CL-Sepharose or 
concanavalin) was first used in stepwise synthesis of a tripeptide Leu-Phe-Phe-OEt. At 
each step before coupling, the C-terminal ethyl ester was removed by CPY at pH 8.5 and 
subsequently coupled with the next amino acid ethyl ester 316. In another example, 
immobilized CPY was used to remove the ethyl ester group from the starting peptide, N-
terminally blocked by carboxymethyl poly(ethylene glycol) (CM-PEG), CM-PEG-Gly-
Met-OEt. The resulting peptide was stepwise elongated at the C-terminus by CPY-
catalyzed removal of the ethyl ester group before each coupling step. The final peptide 
was released by cyanogen bromide cleavage (Fig. 21) 315. Another prospect is the use of 
enzymes that have high esterase/protease ratio. Examples of such enzymes include 
alkaline protease from Bacillus sublitilis DY (similar to subtilisin Carlsberg), Alcalase 
(subtilisin A, a serine endopeptidase from Bacillus licheniformis), and thermitase (a 
serine protease from Thermoactinomyces vulgaris). These enzymes have high 




The risk of protease dependent peptide hydrolysis can be avoided by using 
enzymes lacking amidase activity, e.g. lipases. Lipases incur several advantages over 
proteases. Many commercially available and inexpensive lipases accept a wide range of 
substrates including D-amino acids, and work at the interface of water and organic 
solvents 322. An example of a lipase-cleavable C-terminal protecting group is the heptyl 
(Hep) ester. Heptyl esters were synthesized by azeotropic esterification of amino acids 
with n-heptanol in p-toluenesulfonic acid. The resulting crystalline salts were coupled 
with N-terminally Z-, Boc-, and Aloc- protected amino acids to give the respective 
dipeptide heptyl esters (Fig. 22). Lipase from the fungus Rhizopus niveus hydrolyzed C-
terminal heptyl esters from the resulting dipeptides without interfering with the N-
protecting groups or internal amide bonds (Fig. 22). However, the conversion was low if 
there was a hydrophobic C-terminal amino acid in the dipeptide (e.g. phenylalanine) 321. 
Another lipase from Mucor javanicus was used to deprotect heptyl esters present in labile 
amino acid derivatives and the reaction proceeded without any undesirable side 
reactions 323. This lipase was used for chemoenzymatic synthesis of O-glycopeptides 
which are very sensitive to acid- or base- treatments during chemical deprotection steps 
323,324. It was observed that the activity of lipase was lower in cases where the 
hydrophobicity of the peptide was higher (making substrates less soluble and accessible 
to the lipase), a problem partly due to the high hydrophobicity of the heptyl group. 
 
Fig. 21. Peptide de-esterification by Sepharose-immobilized carboxypeptidase Y (CPY) as a 







H-AA1-OEt EDC, pH 6 
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Furthermore, hydrophobic N-protecting groups like Fmoc also added to the 
hydrophobicity of peptides 321,324. 
To make the substrates more accessible to lipases and increase the solubility of 
peptides in general, hydrophilic heptyl analogs were used as carboxyl protecting groups, 
for example by using a 2-N-(morpholino)ethyl ester (MoEt ester) or a 
(methoxyethoxy)ethyl ester (MEE ester). Another lipase (lipase CE from Humicola 
lanuginosa) was found to hydrolyze peptide-MEE esters when proline was the C-terminal 
amino acid, which was not possible with lipase N (Fig. 23) 325. This prompted the use of 
lipase-labile polyethyleneglycol (PEG) esters. Fmoc-peptide-PEG esters were hydrolyzed 
at the C-terminus to release the Fmoc-peptides in neutral media 325. Lipases and lipase-
labile C-terminal protecting groups have been used to synthesize small peptides and 
peptide conjugates including glycol- and nucleopeptides 326,327. A lipase from Candida 
antarctica (Cal-A) was used for the removal of methyl- and benzyl- esters of N-
(Boc/Z)protected amino acids and peptides, requiring longer reaction times and giving 
lower yields as compared to amino acid substrates 328. 
 
Fig. 22. Chemical synthesis of amino acid heptyl ester and subsequent coupling to yield C-
terminal peptide-heptyl esters. Lipase N (from Rhizopus niveus) catalyzed the removal of heptyl 
ester to yield peptides with free carboxyl end 321. AA = amino acid. P = Z-, Boc- or Aloc- protecting 
group. R = H (Gly), CH3 (Ala), CH(CH3)2 (Val), CH2CH(CH3)2 (Leu), CH(CH3)CH2CH3 (Ile), CH2OH (Ser), 





In addition to lipases, butyrylcholine esterase was also used to remove the C-
terminally protected peptide choline esters groups. Choline esters were synthesized to 
enhance the solubility of hydrophobic peptides (another hydrophilic analog of the heptyl 
ester protecting group). Peptide choline esters were synthesized either by reacting 
peptide 2-bromoethyl esters with triethylamine or by condensing amino acid choline 
esters with amino acids having a free carboxy end. As with lipases, ester removal occurred 
under mild conditions without affecting any internal amide linkages 329. Choline 
esterases such as butyryl choline esterase (BChE) and acetylcholine esterase (AChE) have 
been used to hydrolyze sensitive peptide conjugates, including phosphorylated and 
glycosylated peptides, lipidated peptides and nucleopeptides 327,329,330. An esterase from 
Bacillus subtilis (BsubpNBE) was shown to selectively hydrolyze C-terminal tert-butyl 
esters of N-(Boc)-amino acids, but the enzyme did not accept any peptide tert-butyl ester 
as substrate 331. Another esterase from B. subtilis (BS2) was found to hydrolyze C-terminal 
methyl, benzyl, and allyl esters of N-(Boc/Z) protected amino acids and dipeptides with 
high product yields 328. 
 
  
Fig. 23. Chemical synthesis of amino acid MEE esters and subsequent coupling to yield C-
terminal peptide-MEE esters. Lipase N (from Rhizopus niveus) catalyzed the removal of the 
MEE ester group to yield peptides with a free carboxyl end. AA = amino acid. P = Fmoc-, Z-, 
or Aloc- protecting group. TsOH = p-toluenesulfonic acid. R = CH2OH (Ser), CH(OH)CH3 (Thr). 
EEDQ = ethyl-2-ethoxy-1,2-dihydro-1-quinolinecarboxylate (condensing agent). EDC = 1-
ethyl-3-(dimethylaminopropyl)carbodiimide. HOBt = 1-hydroxybenzotriazole. 
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3.1.2.4 Amidation  
Carboxamides are also considered as suitable carboxyl protecting groups for 
peptides and amino acids. C-terminal amides are abundantly found in natural peptides 
where the amide group serves to protect the peptide from exoprotease activities and 
makes the peptide more biostable. Moreover, many therapeutic peptides and hormones 
are active only in the form of C-terminal carboxamides 2,332,333. These characteristics have 
triggered research on the introduction of carboxamide groups in peptide modification 
reactions, which is also relevant in case of chemoenzymatic peptide synthesis in the 
N→C direction. In the N→C directed peptide synthesis, amino acid building blocks are 
used that are temporarily protected at the C-terminus and are usually activated as alkyl 
esters before enzymatic coupling by a protease 334. 
Carboxypeptidase CPD-Y has been used for peptide C-terminal amidation by 
accepting amino acid amides as the nucleophiles, thus extending the non-activated 
peptide with an amino acid amide. CPD-Y has very low peptidase activity at high pH (and 
still a high esterase activity). Catalysis proceeds via an acyl-enzyme intermediate. This 
property was exploited by using different nucleophiles at high pH (e.g. ammonia or an 
amino acid amide) to produce amino acid amides with up to 100% yield (Fig. 24) 335. 
Transacylations with N-benzyl-Ala-OMe and N-benzyl-Ala-OEt esters with different 
amino components was also investigated. CPY-Y catalyzed the conversion of such methyl 
and ethyl esters into amides, giving the highest yields with amino acid amides (70-98%) 
as the nucleophiles. Among the amino acid amides tested as amine components, only 
isoglutamine amide and prolineamide were not accepted for amide bond formation. 
Furthermore, none of the dipeptides included in the study were accepted as 
nucleophiles, in agreement with the exoprotease activity of the enzyme 336. The 
transpeptidation activity of CPD-Y was used to modify growth hormone releasing factor 
peptide GRF(1-29)-OH to the amidated peptide GRF(1-29)-NH2 using a C-terminal 
 
Fig. 24. Summary of transacylation reactions catalyzed by carboxypeptidase Y with different 
nucleophiles. Best yields were reported for Z-Ala-Ala-OH as the substrate while glycine 
amide (AA3) was the nucleophile (100% yield for Z-Ala-Gly-NH2). AA2, in this case Ala, serves 




alanine in peptide GRF(1-28)-A-OH as the leaving group and Arg-NH2 as the nucleophile 
337.  
Industrial alkaline protease (Alcalase) has been used to catalyze the synthesis of 
amino acid- and peptide amides from the respective N-protected amino acid- and 
peptide methyl esters. Alcalase catalyzed this conversion with ammonium chloride in 
triethylamine as a source of nucleophilic ammonia in anhydrous tert-butanol. Amide 
formation occurred in a kinetically controlled manner where the nucleophile ammonia 
attacked the acyl-enzyme intermediate. Synthetic yields were substrate dependent (44-
75%) and reactions were accompanied by some hydrolysis of the ester substrate (3 – 8 %) 
(Fig. 25) 338. Subtilisin A from Bacillus licheniformis (another alkaline serine protease), 
was used to convert peptide esters to peptide amides via ammonolysis in organic media 
with low water content and ammonium carbamate as an ammonia source. In this 
kinetically controlled conversion, the enzyme showed a high preference for non-polar 
amino acids at the C-terminus and the peptide sequence appeared to have a significant 
effect on the amidation/hydrolysis ratio (Fig. 26) 339. Two more commercial Alcalases 
(Alcalase 2.4L FG and Alcalase 2.5L, type DX) were used as immobilized enzymes in sol-
gel and tested in a batch and in a continuous reactor for the same conversion (Z-Ala-Phe-
OMe to Z-Ala-Phe-NH2, Fig. 26). Higher yields were obtained, but hydrolysis of the ester 
was still observed (10% in case of the continuous reactor system) 340. 
Recently, subtilisin A was used as cross-linked enzyme aggregate (Alcalase-CLEA) 
to achieve better stability and activity in an anhydrous organic solvent. Peptides were 
added as ammonium salts. The enzyme preferred peptides over amino acids without 
hydrolyzing any internal peptide bonds with product yields up to 94%. The reaction 
media had low water content to avoid hydrolysis. Using this method, N-terminally 
protected, side-chain protected and fully unprotected peptides were amidated without 
any side reactions (Fig. 27) 341. In the same study, lipase B from Candida antarctica (Cal-
B) was also investigated to synthesize peptide amides after hydrolysis of peptides with 
Alcalase-CLEA initially observed. Cal-B catalyzed the amidation of C-terminal 
carboxylate groups of peptides in anhydrous solvent either with ammonium salts of α-
carboxylic acids or using ammonia, the latter giving higher yields and faster reactions 
 
Fig. 25. Mechanisms of amide formation catalyzed by Alcalase 338. 
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(Fig. 28). However, Cal-B appeared limited in its substrate scope and bulky amino acids 
were not well accepted (e.g. Phe, Tyr, Trp, or Arg) 341.  
Another enzyme, peptide amidase from the flavedo of oranges, has also been 
investigated for C-terminal amidation of amino acids and peptides. In contrast to the 
proteases mentioned above for the amidation of the carboxy terminus, peptide amidase 
 
Fig. 26. Kinetically controlled synthesis of Z-Ala-Phe-NH2 by subtilisin A with 87% yield. 
 
Fig. 27. Alcalase-CLEA mediated amidation of peptide ammonium salts in organic media. 
Molecular sieves were added to the reaction mixture to maintain an anhydrous 
environment. X = amino acid side chain, Y = Peptide 341. 
 
Fig. 28. Lipase Cal-B mediated amidation of peptides in organic media. Molecular sieves 
were added to the reaction mixture to maintain an anhydrous environment. X = amino acid 





could not be used for kinetically controlled amidation, owing to its lack of esterase 
activity. As the equilibrium favors hydrolysis in aqueous media, earlier attempts to use 
ammonium acetate in water-miscible solvents did not yield any amidation. However, in 
acetonitrile and small amounts (5%) of water, peptide amides were obtained by using the 
dipeptide Z-Gly-Phe-OH as the acyl component and ammonium carbonate or 
ammonium phosphate as the ammonium source (Fig. 29) 342. Amidation occurred at a 
slightly alkaline pH which was controlled by the concentration of the nucleophile. The 
amidation reaction was limited in the substrate range (with a preference for bulky 
hydrophobic amino acids), and the conditions needed to be optimized for each substrate 
due to concurrent precipitation of peptides in the form of ammonium salts. Thus, the 
precipitated peptide substrates were excluded from the reaction mixture 342. The 
synthesis was later optimized by adding as cosolvents DMF and DMSO to the 
acetonitrile-water mixture. Amidation of different N-protected di- and tripeptides was 
achieved but longer peptides were poorly accepted as substrates. Moreover, the poor 
solubility of some substrates and inactivation of the enzyme during the course of the 
reaction posed further challenges 343. 
 
Fig. 29. Peptide C-terminal amidation catalyzed by peptide amidase from flavedo of 
oranges. Y = peptide, X = amino acid side chain. The yield was later optimized by adding 
cosolvents to the system up to 60% 342,343.  
3.1.2.5 De-amidation 
Besides hydrolysis of peptide esters, discussed above, carboxypeptidase Y can also 
hydrolyze peptide amides, similar to the native activity, with release of the C-terminal 
amino acid amide and expose a free carboxyl group on the C-terminus344. Deamidation 
of peptide amides can occasionally also be accompanied by ester formation, as found 
with Alcalase-CLEA. The reaction was performed in anhydrous medium with stabilizing 
cosolvents and fully selective amide to methyl ester interconversion was achieved in high 
yields (Fig. 30). Using this scheme, a chemotactic peptide antagonist, Boc-Met-Leu-Phe-
OH, was synthesized in a stepwise manner where deamidation, esterification, and 
coupling steps were catalyzed by Alcalase-CLEA (Fig. 31). Apart from the broad substrate 
range of Alcalase, the applicability is deemed limited due to serious backbone alcoholysis 
in case of longer peptides 334. In the same study, lipase B (Cal-B) was also found to 
General introduction: enzymatic synthesis of bioactive peptides 
 
perform carboxamide to methyl ester interconversion of Cbz-Ala-NH2, but 
interconversion of (di)peptides amides did not give promising yields 334. 
 As mentioned earlier, protease-catalyzed modifications have inherent risks of 
peptide hydrolysis. Although proteases hydrolyze the carboxamide group more easily 
than a peptide bond, selective cleavage of the C-terminal protecting amide group is not 
straightforward because internal peptide bonds still are cleaved as well, making the 
discovery of better enzymes desirable. There are indications that more suitable enzymes 
exist. Peptide amidase isolated from the flavedo of oranges (peptide amidase) was shown 
to selectively hydrolyze peptide amides at the C-terminus with a broad substrate 
specificity (Fig. 32) 345,346. The enzyme was also reported to catalyze the interconversion 
of di- tri- and tetra peptide carboxamides into the corresponding methyl esters, albeit 
with rather low yields of less than 40% 347. Peptide amidase has also been applied for 
separation of racemic mixtures of N-terminally protected amino acid amides including 
non-proteinogenic amino acids. An example is the use of a microbial peptide amidase 
from Stenotrophomonas maltophilia that hydrolyzed N-acetyl-L-neopentylglycine amide 
from a D/L-neopentylglycine amide mixture (Fig. 33) 348. Such hydrolytic peptide 
amidases are discussed in more detail in the following sections because of their relevance 
to this thesis. 
4.1 Peptide amidase 
Steinke and Kula accidentally discovered the first peptide amidase enzyme from 
orange flavedo (Citrus sinensis) while purifying carboxypeptidase C in an attempt to 
obtain a novel enzyme for enzymatic peptide synthesis 349. It was the first time that a 
selective enzyme was found that catalyzed the hydrolysis of the C-terminal amide group, 
releasing ammonia from peptide amides without hydrolyzing any internal peptide 
bonds. Earlier attempts to use amides as a C-terminal protecting group in peptides were 
problematic due to imminent partial hydrolysis catalyzed by proteases during amide 
hydrolysis. The enzyme accepted both N-protected amino acids and peptide amides as 
substrates, and was selective for L-amino acid amides. The enzyme was shown to retain  
 
Fig. 30. Alcalase-CLEA catalyzed conversion of Z-Phe-NH2 into primary alkyl esters. R = 
methyl-, ethyl- or benzyl-. Reactions were performed either in MTBE, THF or DMF/THF (1/9, 
v/v), with added 3Å and 5Å molecular sieves. Yields: methyl ester, 98%; ethyl ester, 90%; 







Fig. 31. Alcalase-catalyzed steps during the synthesis of the chemotactic peptide antagonist 
Boc-Met-Leu-Phe-OH. All steps were catalyzed by Alcalase-CLEA while the last hydrolysis 
step was performed by peptide amidase. MS = molecular sieves. 
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around 30% of amidase activity in the presence of 30% dimethylformamide (used to 
solubilize peptides)345. Further investigations with partially purified peptide amidase 
showed that the enzyme had a wide substrate range, accepted a variety of di-, tri- and 
tetra-peptides, but not proline- and N-unprotected amino acid amides, tolerated D-
amino acids at the penultimate position, and was not affected by N-terminal peptide 
modifications. Peptide amidase preparations had the highest level of activity when 
isolated from unripe oranges and fully selective amidase activities were recorded for a 
wide range of amino acid and peptide amide substrates. Even glycosylated peptide 
amides were deprotected. The rate of deamidation was reported to be low whenever the 
C-terminus was a bulky hydrophobic amino acid amide (e.g. Z-Trp-NH2) 346. 
In a proof of principle study, Schwarz et al. used the peptide amidase from orange 
flavedo (now denoted as PAF) in conjunction with carboxypeptidase-Y (CPD-Y) to 
synthesize Kyotorphin (a neuroactive peptide, H-Tyr-Arg-OH) in a continuous reactor 
where the two enzymes were separated by ultrafiltration membranes. CPD-Y catalyzed 
peptide bond formation between Tyr-OEt and Arg-NH2. The resulting dipeptide amide 
(TyrArg-NH2) was hydrolyzed to the free carboxyl terminus peptide (TyrArg) by PAF 350. 
PAF was later studied further and characterized by Steinke et al. PAF was a 23±3 kDa 
protein, had an optimum pH of 7.5±1.5, optimum temperature of 30oC at pH 7.5, an 
isoelectric point of pH 9.5, and was stable from pH 6 to 9. PAF was also studied for the 
reverse reaction (i.e. amidation) as mentioned above 351. The enzyme was believed to lack 
esterase activity, but Quaedflieg et al. later used PAF to convert oligopeptide amides to 
 
Fig. 32. Hydrolysis of peptide amides by peptide amidase from orange flavedo. X = amino 
acid side chain, Y = amino acid- or peptide- residue, or N-terminal protecting group. 
 





oligopeptide esters 347. PAF, however, is not well characterized to date and has not been 
obtained via microbial fermentation because the gene is unknown. Moreover, the yields 
obtained are low and the original method of extraction from orange peels makes it a 
laborious task to use it in peptide synthesis. 
A microbial peptide amidase, from Stenotrophomonas (Xanthomonas) 
maltophilia, was discovered by screening strains known for deamidating carnitine amide 
against Z-Gly-Tyr-NH2 as the substrate. This bacterial peptide amidase, Pam, had a native 
molecular mass of 38 ± 3 kDa and similar to PAF, did not contain any protease and 
peptidase activity. Also similar to PAF, Pam was stable at 30oC but had a different pH 
optimum (pH 5 to 6) and isoelectric point (5.8). Pam catalyzed deamidation of N-
protected amino acid- or peptide amides. N-unprotected peptide amides were accepted 
as substrates but unprotected amino acid amides were not accepted. The enzyme showed 
a broad substrate range, but like with PAF, peptide amides with proline at the C-terminus 
were not converted. Pam was stereoselective for the C-terminus of peptides and amino 
acid amides, did not accept D-amino acid amides, which were however tolerated at the 
penultimate position. A high concentration of serine protease inhibitors was required to 
inhibit the enzyme suggesting a non-specific inhibition or weakly reactive serine. Similar 
to PAF, it was deemed that Pam would be a valuable tool for deamidation in a stepwise 
chemoenzymatic peptide synthesis scheme 352. In a comparison study, Stelkes et al. used 
both PAF and Pam for the resolution of amino acid derivatives. N-acetyl aromatic amino 
acid amides (except N-acetyl-phenylglycine-NH2) and also N-acetyl-Met-NH2 were 
better substrates for Pam than the model substrate (Z-Gly-Tyr-NH2). Apparently, a 
methylene group in the β-C position facilitated deamidation by rendering the side chain 
more flexible and lowering the steric constraints in the binding site of the enzyme. The 
enzyme gave the maximum yield of 50% with respect to the racemic substrate tested in 
the study 353. 
Neumann et al. identified the Pam gene by Southern hybridization and cloned it 
in E. coli strain Origami DE3 354. Pam was found to be a periplasmic protein based on the 
N-terminal sequence. Sequence analysis also showed that Pam is a member of amidase 
signature family having a conserved amino acid signature sequence – GGSS[GS]G 355. A 
truncated protein, devoid of the N-terminal signal sequence, was expressed and found 
to have better specific activity compared to the native enzyme isolated from S. 
maltophilia. The recombinant enzyme appeared to have a larger molecular weight (≈50 
kDa in native state without the N-terminal sequence, in contrast to the originally 
reported MW of 38 kDa), and also had slightly different pH and temperature optima 
compared to previous data (pH 7.0–8.2 and 46–54 oC, in contrast to pH 5.0–6.5 and 37–
45 oC). Substrate spectrum studies revealed that dipeptide amides were the best 
substrates while ultimate and penultimate amino acid residues had a major impact on 
the enzyme activity. Different versions of the recombinant enzyme based on N-terminal 
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or C-terminal truncations exhibited variations in activity 354. Pam was expressed without 
the N-terminal sequence as a cytoplasmic protein with a C-terminal 6x His-Tag. The 
investigators further carried on to crystallize this peptide amidase and the X-ray 
crystallographic structure of Pam was obtained 356.  
Both Pam and PAF were found to have a broad substrate range. From the 
literature, it appears that the substrate specificities for both enzymes overlap. Peptide 
amidases have a preference for dipeptide amides. With amino acid amides, PAF shows 
better activity than Pam while proline was not accepted by both amidases at all. The 
available data suggest that PAF prefers bulky groups at the penultimate position. Both 
enzymes prefer L-amino acids as amino acid amide substrate or within a peptide amide. 
Enzyme activity decreases in general by increasing the length of the amino acid amide 
chain 345,352–354. 
4.1.1 Structure and mechanism of Pam amidase 
Pam belongs to the amidase signature (AS) family of amidases, a highly diverse 
family of enzymes according to their substrate specificity and function (InterPro domain 
IPR023631). AS amidases catalyze amide bond (CO-NH2) hydrolysis and are 
characterized by the presence of a highly conserved, serine/glycine-rich motif 
(GGSS[G/S]G) located in a highly-conserved stretch of ca. 130 amino acids, called the 
amidase signature sequence. The signature sequence region also holds the conserved Ser-
(cis)Ser-Lys catalytic triad 357,358. Examples of AS enzymes other than Pam are: 1) fatty 
acid amide hydrolase (hydrolyzes fatty acid amide substrates e.g. cannabinoid 
anandamide) 359, 2) malonamidase E2 (hydrolyzes malonamate) 358, and subunit A of 
Glu-tRNA(Gln) amidotransferase (catalyzes transamidation of misacylated Glu-
tRNA(Gln) via amidolysis of glutamine) 360. 
Pam has been crystallized with and without the inhibitor chymostatin (Cst). Its 
structure has been solved to 1.4 Å resolution 361. Chymostatin inhibits serine-proteases 
by forming acyl-adducts with the serine nucleophile in the protein. In case of Pam, 
Chymostatin was found non-covalently bound in the active site. According to the crystal 
structure data, Pam folds in a conical structure consisting of double layers of α-helices 
surrounding a mixed 11-stranded β-sheet core. The AS domain is formed by a five-
stranded β-sheet covered by four α-helices. The active site residues are present in a pocket 
located at the bottom of this fold (Fig. 34, and 35). The Ser-(cis)Ser-Lys catalytic triad is 
reminiscent of the classic Ser-His-Asp triad of serine hydrolases allowing the formation 
of an extended hydrogen-bond network between enzyme and substrate, and an oxyanion 
pocket that stabilizes the tetrahedral reaction intermediates. In AS enzymes, the unusual 
(cis)-Ser-Lys pair replaces the functional role of His-Asp, but the placement of the 
catalytic triad in the active site is different. It appears that the catalytic Lys can directly 
interact with the substrate which is important for substrate orientation in the active site, 




interacts only with His 362. Apart from similarities in structure, the AS amidases act upon 
a diverse range of substrates with different enzymes proposed to have a different 
mechanism for the formation of acyl-enzyme intermediate 361,363–365.  
The description of the catalytic mechanism of Pam could be improved on the basis of 
computational studies on Pam and malonamidase E2 (MAE2) by Valina et al. and 
Cerqueira et al., respectively 362,363. A general mechanism was proposed that details the 
proton transfer steps during the catalysis, and Fig. 36 outlines the most likely mechanism 
of peptide amidase (Pam). The essential feature is the formation of an acyl-enzyme 
intermediate that is subsequently hydrolyzed to yield the product. In the first chemical 
step, Ser226 performs a nucleophilic attack on the amide carbonyl carbon of the 
substrate. This reaction is facilitated by the hydrogen bond network between the 
catalytic Ser, (cis)Ser, and Lys residues. Ser226 becomes ionized by transferring its 
proton to (cis)Ser202 that in turn protonates Lys123. The oxyanion pocket, formed by 
backbone NH groups of Thr223, Asp224, and Ser226, stabilizes partial negative charge 
on the amide carbonyl oxygen, increasing its sensitivity to nucleophilic attack. As a result, 
the carbonyl carbon of the substrate becomes covalently bonded to Ser226 forming a 
negatively charged tetrahedral intermediate. The oxyanion pocket stabilizes the negative 
charge on the substrate carbonyl oxygen throughout the next step. The original proton of 
 
Fig. 34. Two views of the Pam 3D structure (rotated 180o) showing the secondary structure 
elements. The inner -sheet core is colored in red, surrounded by α-helices in blue. The loops 
are colored purple. The inhibitor chymostatin is represented with a yellow backbone. A 
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Ser226 is now bonded with (cis)Ser202, which in turn donates its proton to Lys123, 
making the latter positively charged. In the second step, Lys123 transfers a proton to 
(cis)Ser202, which in turn protonates the amide (leaving) group of the tetrahedral 
complex while the negative charge on the carbonyl carbon is being stabilized by the 
oxyanion pocket. In the third step, the tetrahedral intermediate collapses, releasing NH3 
and forming the covalent acyl-enzyme intermediate. The hydrogen bonding network 
between the carbonyl oxygen of the substrate and the oxyanion pocket becomes weak. 
The next two steps conclude the hydrolysis of the acyl-enzyme-intermediate, 
which requires a water molecule. The oxyanion hole stabilizes the covalent intermediate 
until hydrolysis. (cis)Ser202 protonates Lys123 and in turn is protonated by the water 
molecule. Simultaneously, the carbonyl carbon receives the hydroxyl group, the oxygen 
develops negative charge, which is now stabilized by Ser226, Asp224, and Thr223 of the 
oxyanion hole. In the last step, Lys123 protonates (cis)Ser202 which in turn protonates 
Ser226, detaching it from the acyl-enzyme intermediate. The resulting product, the 








Fig. 35. Close view of the active site pocket 
of Pam. (A) Cartoon diagram with the 
inhibitor Chymostatin (blue backbone). (B) 
Cartoon diagram with the model substrate 
Z-Gly-Tyr-NH2 (blue backbone) docked into 
the active site pocket (green backbone). The 
channel from the active site is represented 
as orange mesh. (C) Active site view in the 
surface mode. Docking was performed with 
the help of DockingApp software, using the 
AutoDock Vina algorithm. The tunnel was 
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5.1 Goal and outline of the thesis 
The present work aims to discover more suitable enzymes for the modification of 
the C-terminus of peptides in order to facilitate the use of chemically synthesized 
peptides in enzymatic fragment coupling. Important reactions would be 
thermodynamically controlled amidation of the free carboxylate as well as kinetically 
controlled deamidation and esterification of the carboxamide moiety of peptide amides. 
A suitable biocatalyst should be resistant to organic cosolvents and active at low water 
content. Such an enzyme may catalyze deprotection and activation of a peptide via 
deamidation and esterification in a single step. Of the two peptide amidases that have 
been described in the literature, one (peptide amidase from the flavedo of oranges, PAF) 
has been reported to catalyze the desired methyl ester synthesis reaction, but hydrolysis 
was still the main conversion and large amounts of enzyme were required 347, indicating 
that better kinetic properties or improved activity at low water content is needed. 
Furthermore, neither this enzyme not any other plant peptide amidase has been 
biochemically characterized. The second known peptide amidase (Pam from 
Stenotrophomonas) has been cloned and expressed in bacteria but peptide C-terminal 
esterification has not been documented. An enzyme catalyzing the desired C-terminal 
modifications would be an ideal catalyst to materialize the C-terminal extension strategy 
for chemo-enzymatic peptide synthesis described above. Such an enzyme would also be 
useful for other reactions leading to C-terminal peptide modification, especially if they 
can be applied in neat organic solvents or solvent mixtures that facilitate peptide and 
reactant coupling.  
Chapter 1 provides a general introduction to the field of peptides, their 
applications in health and food, and recent advances in the field of peptides synthesis. 
Strategies for peptide synthesis are reviewed and different ways to achieve protection and 
deprotection of amino acids and peptides are also described. In the last section of this 
Chapter, we discuss peptide amidases available to date and in particular, the peptide 
amidase from Stenotrophomonas maltophilia is discussed, which is the only peptide 
amidase of which a crystal structure has been reported.  
Chapter 2 describes the discovery and characterization of a peptide amidase from 
Glycine max (soybean) by cloning cDNA. It was identified as a homolog of a peptide 
amidase that we detected by mass spectrometry in partially purified protein preparations 
of Citrus flavedo or in a commercial preparation of peptide amidase.  
Chapter 3 presents the use of peptide amidase Pam from Stenotrophomonas 
maltophilia for esterification of peptides and shows the use of enzymatically esterified 
peptide in peptide coupling mediated by a subtilisin variant. 
Chapter 4 discusses the development of a highly thermostable Pam using 




discovered and combined, leading to a highly stable and solvent compatible enzyme. 
Different coupling reactions that can be performed by the stabilized enzyme and its use 
in organic solvents are discussed as well. 
Chapter 5 discusses mutagenic studies to improve the thermostability of the 
peptide amidase from Glycine max. The results show that stability can be enhanced by 
the introduction of mutations that replace amino acids that are very different from 
consensus in the native sequence. 
The thesis concludes with a general discussion in Chapter 6. A review of the 
findings reported in this thesis and the role of peptide amidases in chemo-enzymatic 
peptide synthesis will be discussed. 
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